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Post-traumatic stress disorder (PTSD), a trauma- and stressor-related disorder, is a condition that 
can develop in response to life-threatening situations.  According to the Diagnostic and 
Statistical Manual of Mental Disorders 5 (DSM-5), a diagnosis of PTSD necessitates exposure to 
a life-threatening event, intrusive recollections, avoidance of associated stimuli, hyperarousal, 
and a significant social impairment.  All of these symptoms must persist for at least 30 days and 
not be due to illness, medication, or substance abuse.  To date, no definitive diagnostic 
biomarkers have been identified for PTSD.  Recent research, however, points toward 
physiological abnormalities in the brain, hypothalamic-pituitary-adrenal (HPA) axis, and 
immune system that may be partially responsible.  Many chronic conditions such as 
hypertension, heart failure, and metabolic syndrome perpetuate in a state of increased 
inflammation and oxidative stress, exacerbating their pathophysiology.  In many psychiatric 
conditions such as depression and anxiety disorders, neurotransmitter modulation may play a 
critical role in their pathogenesis.  Based upon the literature and work from our laboratory, we 
hypothesized that similar pathophysiological mechanisms may play a role in PTSD development.  
We tested our theory by creating a PTSD-like syndrome in rats with the use of a predator 
exposure/psychosocial stress animal model.  We then conducted a series of in vivo and ex vivo 
experiments in an attempt to discover the roles of inflammation, oxidative stress, and 
neurotransmitter modulation in PTSD development.  First, we evaluated inflammation and 
oxidative stress in the brain, adrenal glands, and blood in response to the predator exposure 
model.  We then analyzed neurotransmitter modulation in the hippocampus and prefrontal 
cortex.  Next, we investigated the anti-inflammatory and neuromodulating effects of the histone 




neurotransmitters.  Finally, we employed the selective-serotonin reuptake inhibitor (SSRI) 
sertraline to ascertain why SSRIs have historically been ineffective in treating PTSD.  Taken 
together, our findings indicate inflammation, oxidative stress, and aberrant neurotransmitter 
profiles may play a significant role in PTSD development and progression.  In addition, VA may 
prove to be a legitimate pharmacologic alternative in PTSD treatment, as SSRIs may increase the 































INTRODUCTION AND LITERATURE REVIEW 
 
1.1 BACKGROUND AND EPIDEMIOLOGY OF PTSD 
 The term post-traumatic stress disorder (PTSD) was first introduced as a diagnosis in the 
Diagnostic and Statistical Manual of Mental Disorders III (DSM-III) in 1980 (American 
Psychiatric Association, 1980).  Trauma- and stress-related disorders, however, have probably 
existed since the beginning of recorded history.   Trimble believed Shakespeare’s Henry IV, 
written over 400 years ago, displayed many of the symptoms currently associated with PTSD 
(Trimble, 1985).  Ezra even describes trauma-related stress reactions dating back to 2100 BC, 
when King Urnamma was killed in battle in the ancient city of Ur and citizens of the city 
subsequently experienced sleep disturbances (Ezra, 2001).  Since then, what is now known as 
PTSD has been described by many different names.  Soldier’s heart, shell shock, stress-response 
syndrome, and battered woman syndrome are among the many, but they all seem to possess 
similar symptoms.  It seems evident that some type of stress response to extremely traumatic 
situations has long been a part of the human condition.  
 Lifetime prevalence rates for PTSD in the United States are estimated to be between 8-
14%, with current rates close to 15%.  For combat veterans, estimates range as high as 31% 
(Magruder et al., 2004).  The average age of onset for PTSD is 23, but the highest incidence is 
reported in the 45-59 year-old age group (Kessler et al., 2005).  In post-conflict countries, the 
rates are considerably higher.  In a study by de Jong et al. of four countries with a history of 
conflict, they reported PTSD rates of 37% in Algeria, 28% in Cambodia, 18% in Gaza, and 16% 
in Ethiopia (de Jong et al., 2001).  There also appear to be gender differences in prevalence rates.  
According to a recent report, women are twice as likely as men to develop PTSD, but the reasons 




diagnosed with PTSD responded considerably stronger to traumatic visual cues than male PTSD 
patients (Inslicht et al., 2013).  The rationale behind these findings could be biological, 
psychological, social, or a combination of these factors and others.  In various animal models of 
PTSD, the results are the opposite.  Male animals tend to be more susceptible to stress, whereas 
females are considerably more resilient (Cohen & Yehuda, 2011).  Studies have also shown that 
susceptibility to stress in females varies with their menstrual cycle.  During lower estrogen levels 
(follicular phase), females tend to have impaired fear inhibition, but during higher estrogen 
levels (luteal phase), estrogen may be protective (E. M. Glover et al., 2013).  Men, on the other 
hand, tend to underreport psychiatric symptoms, further blurring the lines between gender 
differences (Peters, Issakidis, Slade, & Andrews, 2006).  It is clear that further research into 
gender susceptibility and response is necessary. 
 One of the unique features of PTSD is that it rarely occurs as an isolated diagnosis, and 
comorbidity with other disorders is more the rule than the exception.  Data from the National 
Comorbidity Survey indicate that 88.3 percent of men and 79.0 percent of women diagnosed 
with PTSD meet the criteria for at least one other psychiatric disorder, with many of those 
meeting the criteria for three or more (Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995).  The 
most common comorbid disorders with PTSD are depressive disorders, substance abuse 
disorders, and other anxiety disorders.  According to Brady et al., females with PTSD are 4.1 
times as likely to develop depressive disorders and 4.5 times as likely to develop mania as 
women without PTSD.  Men who have PTSD are 6.9 times as likely to develop depression and 
10.4 times as likely to develop mania as men without PTSD (Brady, Killeen, Brewerton, & 
Lucerini, 2000).  In addition, a large portion of both males and females with PTSD experience 




common occurrence among PTSD sufferers, and it is estimated that approximately 20% have 
attempted suicide at least once (Davidson, Hughes, Blazer, & George, 1991).   
 Despite the increase in PTSD research in the last 10-15 years, it is difficult to determine 
if rates are increasing or remaining stable.  According to Brunet, global PTSD diagnoses 
remained relatively unchanged from 1997-2007.  The article states that while PTSD criteria have 
become stricter over the years, mental health professionals have become better at correctly 
assessing and identifying PTSD, leading to diagnoses that may have previously been missed 
(Brunet, Akerib, & Birmes, 2007).  The true number of those suffering from PTSD, however, 
may never be known.  In certain subgroups such as battered women, inmates, and the homeless, 
they may not have the resources or ability to seek help.  There also exists a prevailing social 
stigma that might cause those in certain professions to downplay their symptoms for fear of 
being ostracized.  Current diagnostic approaches for PTSD are self-assessment questionnaires 
and mental health provider interviews, which although effective rely exclusively on the 
candidness of the patient and are thus inevitably subjective.  This subjectivity can result in 
missed diagnoses, underreported symptoms, or even malingering, which necessitates better 
diagnostic tools.  To this end, exploring the pathophysiology occurring in the brain and body 
during progression of the disorder may lead to the discovery of PSTD biomarkers and greatly 
improve the accuracy and speed of PTSD diagnoses and treatment.              
1.2 PATHOPHYSIOLOGY OF PTSD 
 PTSD, an anxiety disorder recently reclassified as a trauma- and stressor-related disorder, 
can develop in response to real or perceived life-threatening situations.  According to the DSM-
5, a diagnosis of PTSD necessitates exposure to a life-threatening event, intrusive recollections 




cognitions/mood, hyperarousal not present before the trauma, and a significant social 
impairment.  All of these symptoms must persist for at least 30 days and not be due to illness, 
medication, or substance abuse (American, 2013).  To date, no definitive diagnostic biomarkers 
have been identified for PTSD.  Recent research, however, points toward physiological 
abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis, sympathoadrenal medullary 
system, immune system, and brain neurotransmitters that may be implicated in the disorder 
(Liberzon, Abelson, Flagel, Raz, & Young, 1999; Oosthuizen, Wegener, & Harvey, 2005; 
Sondergaard, Hansson, & Theorell, 2004; Wilson et al., 2013, 2014). 
1.2.1 Inflammation and Oxidative Stress 
 Exposure to psychologically traumatic events, such as those experienced during combat 
or other situations posing a legitimate threat to safety and survival, place individuals at 
significant risk for developing PTSD.  A growing body of evidence suggests that exposure to 
traumatic stressors and subsequent psychological trauma may result in increased morbidity and 
premature demise of patients.  Much of the data available suggest traumatic exposure and 
subsequent PTSD may lead to increased incidence of cardiovascular disease, diabetes, chronic 
fatigue syndrome, and other conditions (Dansie et al., 2012; Edmondson & Cohen, 2013; Gupta, 
2013; Lukaschek et al., 2013).  Most of these diseases have detrimental inflammatory 
components that may exacerbate their progression.  Inflammation is a critical component of the 
immune response, but acute and chronic inflammation can damage cellular mechanisms.  
Stressful events affect the immune system by reducing the cellular response to mitogen 
stimulation, decreasing production of natural killer cell activity and altering levels of cytokines.  
Cytotoxic T lymphocytes, which regulate the balance between Th1 and Th2 cells, are altered by 




production of pro-inflammatory cytokines (PICs).  These PICs, especially the interleukins, have 
been shown to play an important role in modulating disease processes.  An important and 
detrimental consequence of increased cytokine production is the induction of nitric oxide (NO) 
and reactive oxygen species (ROS) (Hu, Peterson, & Chao, 1998; Mokuno et al., 1994).    
 Elevated levels of PICs and ROS can cause cell death and tissue damage, although the 
cellular mechanisms responsible for initiating these processes during the stress response have 
remained poorly understood.  In addition to leukocytic responses, PIC upregulation may also be 
due to the activation of inflammasomes (Salminen, Ojala, Kaarniranta, & Kauppinen, 2012).  
Inflammasomes are multiprotein complexes that cooperate with pattern-recognition receptors 
(PRRs) such as Toll-like receptors (TLRs) and nucleotide oligomerization domain (NOD)-like 
receptors (NLRs).  When the inflammasome complex is activated, it cleaves pro-caspase-1 into 
its active form, which results in the production of PICs and initiates the inflammatory response 
(Figure 1.1).  When proliferation of PICs exceeds the ability of local cellular receptors to utilize 
them in autocrine or paracrine functions, they become blood-borne.  These cytokines can then be 
transported across the blood-brain barrier (Banks, 2005), where they activate microglial cells and 
induce the production of more cytokines.  The process results in a positive feedback loop, which 
can become self-sustaining and cause systemic organ dysfunction (Figure 1.2).  Research from 
our lab has demonstrated the damaging effects of PICs when quantities reach uncontrolled levels.  
We have also shown that blocking certain downstream transcription factors and gene modifiers 
of these cytokines reduces oxidative stress, inflammation, and associated damage in 
hypertension, heart failure (HF), and metabolic syndrome (MetS) (Elks & Francis, 2010; Elks et 






Figure 1.1: The inflammasome complex, once activated, cleaves pro-caspase-1 into active 
caspase-1, which then cleaves pro-IL-1β and pro-IL-18 into active IL-1β and IL-18.  The active 




Figure 1.2: The upregulation of reactive oxygen species can cause tissue damage, which leads to 
increased cytokines and further upregulation of reactive oxygen. The process results in a 





1.2.2 Histone Deacetylases 
 Inflammation is a critical component of the immune response, but chronic inflammation 
can damage cellular mechanisms.  There are a host of triggers initiating the inflammatory 
response, many of which are initiated via TLR4 and subsequent nuclear factor (NF)-κB 
activation.  Transcription by NF-κB requires DNA and chromatin remodeling, which enables 
access to the pertinent genomic sequences.  Gene expression is regulated via highly controlled 
acetylation/deacetylation of histone N-terminal tails, which either increases or decreases gene 
availability (de Ruijter, van Gennip, Caron, Kemp, & van Kuilenburg, 2003).  
Acetylation/deacetylation is accomplished by histone acetyltransferases (HAT) and histone 
deacetylases (HDAC), which enable and restrict genome access, respectively.  When oxidative 
stress and inflammation are increased, upregulated PICs can correspond with heightened HDAC 
activity and NF-κB transcription, resulting in perpetual PIC production (Keslacy, Tliba, 
Baidouri, & Amrani, 2007).  Although HDACs restrict access for transcription and should 
depress PIC production, the exact opposite may be the case.  The effects of HDAC inhibitors 
(HDACi) extend to non-histone proteins that are reversibly acetylated, which markedly affects 
their function (Nair, Boersma, Schiltz, Chaudhry, & Muschel, 2001; Tong, Yin, & Giardina, 
2004).  This functional shift means HDACs may actually enhance the inflammatory response.  In 
addition to histone modification, HDACs may also modulate neurotransmitters by modifying 
levels of pertinent rate-limiting enzymes (Sharma, Grayson, & Gavin, 2008).  For example, 
tyrosine hydroxylase, the rate-limiting enzyme for dopamine (DA) and norepinephrine (NE) 
synthesis, is depressed by HDACi (Akiba et al., 2010).  Studies have also shown antidepressant 
effects of HDACi (Covington et al., 2009), possibly be due to epigenetic modifications of 




1.2.3 The HPA Axis 
 The HPA axis is a critical component of the central nervous system (CNS) stress 
response.  During a stressful event, afferents from the thalamus and sensory cortex signal the 
amygdala of possible danger.  The amygdala has efferents that project to the hypothalamus, 
where the parvocellular neurons of the paraventricular nucleus (PVN) release corticotropin-
releasing hormone (CRH) at the median eminence and it is carried to the anterior pituitary gland 
via the hypophyseal portal system.  In response, the anterior pituitary releases 
adrenocorticotropic hormone (ACTH) into the systemic circulation.  ACTH causes the release of 
cortisol (corticosterone in rodents and non-humans) from the adrenal cortex, which serves a 
variety of purposes in the stress response.  Primarily, cortisol functions to increase blood sugar, 
depress immune function, and acts as a negative feedback signal at the pituitary and PVN.  In 
PTSD, however, the system may not function in the same manner.  Current research has shown 
that the interaction between cortisol and the immune system may not be as simplistic as 
previously believed.  Cytokines are upregulated in the brain and systemic circulation during the 
stress response (Wilson et al., 2013), which contradicts the belief that cortisol is always 
immunosuppressive.  Researchers have also demonstrated that CRH and glucocorticoids could 
influence the immune system in both directions, indicating a stress response could increase PICs 
and inflammation and alter normal HPA axis function (Chrousos, 1995; Chrousos & Gold, 
1992).   
  Numerous studies have shown PTSD patients to have lower cortisol levels than the 
general population (Yehuda, 2009), but there have also been studies reporting no difference 
(Baker et al., 1999) or elevated levels (Liberzon et al., 1999).  Cortisol functions effectively in a 




(Addison’s disease) both have deleterious effects.  The difference in study results underscores 
the rapid nature of glucocorticoid changes in response to even the slightest stressor, and may 
provide a rationale for often inconsistent results reported in PTSD.  Despite these differences, 
glucocorticoid abnormalities seem to play a legitimate role in PTSD progression, but to what 
extent remains unanswered.      
1.2.4 The Sympathoadrenal Medullary (SAM) System 
 The SAM system works in concert with the HPA axis during the stress response.  The 
system is very complex and most pathways between nuclei are bi-directional with multiple 
connections.  As mentioned previously, the amygdala receives inputs from sensory areas of the 
brain and transmits signals to the appropriate regions for response.  The amygdala and the PVN 
have efferents to the rostral ventrolateral medulla (RVLM), which projects to the spinal cord 
intermediolateral nucleus (IML) (Fisher & Paton, 2012).  The amygdala and PVN also project to 
the locus coeruleus (LC), the brainstem nucleus responsible for most NE synthesis in the CNS, 
which contains sympathetic projections to the IML.  The IML sends preganglionic efferents to 
the adrenal medulla from the thoracic spinal cord, and the adrenal medulla acts as a specialized 
sympathetic ganglion (Sapru, 2007).  In response to stimulation, chromaffin cells in the adrenal 
medulla synthesize and release catecholamines into the systemic circulation.  Catecholamine 
release during stress influences neuroplasticity, memory, emotions, behavior, and other actions 
in the CNS (Benarroch, 2009).  In the systemic circulation, epinephrine and NE increase heart 
rate, trigger glucose release, and prepare the body for a “fight-or-flight” response.   
 The persistent sympathetic drive and noradrenergic responsiveness by the interaction of 
the LC and amygdala have received attention as possible contributors to stress-induced disorders 




number of neurons in the LC, indicating the LC may play a more important role in PTSD 
development than previously believed (Bracha, 2005).  These data support our findings that NE 
is significantly increased in the hippocampus and PFC in response to the predator exposure 
model, and that constant noradrenergic stimulation may be a primary contributor to PTSD 
(Wilson et al., 2014).      
1.2.5 Neurotransmitters  
 Neurotransmitters are small, endogenous chemicals that relay information from one 
neuron to the next at a synaptic cleft.  Most neurotransmitters are packaged in synaptic vesicles 
and released in response to an action potential.  At the post-synaptic cell they act on either 
excitatory or inhibitory receptors, which determines the receiving cell’s response.  Although the 
primary drugs for treating PTSD are the selective-serotonin reuptake inhibitors (SSRI), the 
actions of neurotransmitters in PTSD are poorly understood.  Serotonin (5-HT), for example, is a 
neurotransmitter responsible for many functions in the CNS and peripheral organs.  5-HT 
influences aggression, arousal, sleep, anxiety, appetite, fear, learning, and other actions 
(Dubovsky, 1994).  5-HT is also the principle regulator of mood.  A study by Peirson et al. 
(Peirson & Heuchert, 2000) found lower platelet 5-HT2 receptor function was associated with 
depressed mood, while Williams et al. (Williams et al., 2006) demonstrated higher blood 5-HT 
levels were correlated with better mood.  An increased mood and overall sense of well-being has 
been shown, in both psychiatric and physical disorders, as protective and positively correlated 
with resiliency behavior (Delamothe, 2005).  Research has demonstrated that 5-HT uptake sites 
in platelets were lower in PTSD patients vs. controls (Arora, Fichtner, O'Connor, & Crayton, 




showed that a low prolactin response to fenfluramine, a drug that increases 5-HT levels, was 
associated with metabolic syndrome (Muldoon et al., 2004).   
 Norepinephrine (NE) is a neurotransmitter that is also involved in the regulation of 
psychiatric and physical mechanisms.  Under normal conditions, NE is a principle component of 
the stress response, directly increasing heart rate and blood flow to skeletal muscles and 
triggering the release of glucose, all in preparation for the ‘fight-or-flight’ response.  Persistent 
noradrenergic activity, however, has been linked with negative outcomes in patients with 
congestive heart failure (CHF) (Francis et al., 1993) and diabetes (Ganguly, Dhalla, Innes, 
Beamish, & Dhalla, 1986).  Studies have also shown that individuals with PTSD have elevated 
cerebrospinal fluid (CSF) levels of NE (Geracioti et al., 2001) and noradrenergic 
hyperresponsiveness to various stimuli (Liberzon et al., 1999).  Dysregulation of noradrenergic 
neurons has also been associated with hyperarousal and intrusive recollections attributable to 
PTSD (Southwick et al., 1999).  
 Dopamine (DA) is a neurotransmitter that plays a major role in emotion and the reward 
system of the brain.  It optimally functions within a narrow range and dopaminergic hypo- or 
hyperactivity is implicated in both physical and psychiatric illnesses.  Parkinson’s disease is 
characterized by a loss of dopaminergic neurons, and evidence suggests schizophrenia and 
psychosis are linked to elevated levels of DA (Paterlini et al., 2005).  DA may also have a role in 
PTSD, and studies have shown dopaminergic hyperactivity in male combat veterans (Yehuda, 
Southwick, Giller, Ma, & Mason, 1992), traumatized adult females (D. A. Glover et al., 2003), 
and abused children (De Bellis et al., 1999) with PTSD.  The dopamine metabolite homovanillic 
acid (HVA), often used as a diagnostic test for catecholamine-producing tumors of the adrenal 




significantly reduced in the CSF of combat-related PTSD patients immediately after viewing 
traumatic imagery (Geracioti et al., 2013).  Based on the previous research, it is clear that 
elucidating the complex interactions of the numerous neurotransmitter systems may be a critical 
link in understanding PTSD progression.   
1.3 THE HIPPOCAMPUS 
 The hippocampus lies deep in the temporal lobe (Figure 1.3) and is part of the limbic 
system.  It exerts important influences on the endocrine and autonomic systems, and it also 
affects motivation and mood.  It plays an important role in the consolidation of both long term 
and short term memories, and it is chiefly responsible for mediation of stress responses via the 
HPA axis. The hippocampus has been implicated in fear conditioning (Fendt, Fanselow, & Koch, 
2005), spatial memory (Kessels, de Haan, Kappelle, & Postma, 2001), depression (Malberg, 
2004), epilepsy and seizure susceptibility (McEwen & Magarinos, 2001), CNS-mediated 
glucoregulation through cholinergic epinephrine secretion (Uemura et al., 1989), cognitive 
disorders such as Alzheimer’s Disease (Garzon, Yu, & Fahnestock, 2002) and PTSD (Wilson et 
al., 2013, 2014) 
 The hippocampal formation is comprised of six distinct regions, linked by primarily 
unidirectional projections (Hasselmo, 1995).  These regions include the dentate gyrus, the 
hippocampus proper (Cornu Ammonis (CA) 1, 2, 3), subicular cortex (comprised of the 
subiculum, the presubiculum, the parasubiculum), and the entorhinal cortex (composed of two or 
more subdivisions) (Hasselmo, 1995).  Although the neurophysiological roles for each of these 
areas are now being elucidated and reported, distinct functions remain incompletely understood 
and are based mainly on computational models derived from hippocampal connectivity studies 





What is well known and widely reported, however, is that the hippocampus exhibits a large 
degree of functional and structural plasticity and throughout adulthood generates large numbers 
of new neurons (Kozorovitskiy & Gould, 2004; van Praag, Christie, Sejnowski, & Gage, 1999; 





Figure 1.3: Computer generated model of the rat hippocampus illustrating its shape and position 
deep within the temporal lobe of the brain (Laboratory of Neuro Imaging, 2005). 
 
1.4 THE PREFRONTAL CORTEX 
 The prefrontal cortex (PFC) is the anterior portion of the frontal lobe of the brain (Figure 
1.4), and it is considered the executive center for higher order functions such as complex 
behavior and decision-making, personality, and social “control” (Yang & Raine, 2009).  Other 
executive actions of the PFC include determining good vs. bad, actions and consequences, and 
working toward a goal (DeYoung et al., 2010).  The exact definition of the PFC differs among 
researchers, and there are varying descriptions.  It has been characterized by the presence of a 
granular layer IV (only in primates) (Uylings, Groenewegen, & Kolb, 2003), as being the 




& Goldman-Rakic, 1991), and as the area of the frontal cortex whose electrical stimulation does 
not lead to observable movements (contains granular and non-granular areas) (Preuss, 1995).   
 During anxiety and fear responses, the PFC is responsible for the extinction of fear 
conditioning and the retention of extinction (Milad & Quirk, 2002).  This extinction does not 
occur when the PFC is damaged (Morgan, Romanski, & LeDoux, 1993; Quirk, Russo, Barron, & 
Lebron, 2000), and research has demonstrated inflammation and oxidative stress are increased in 
the PFC during PTSD progression (Wilson et al., 2013).  Damage caused by inflammation and 
oxidative stress, coupled with the fact that individuals with PTSD exhibit abnormal fear 
responses and attenuated fear extinction (Orr et al., 2000; Rothbaum, Kozak, Foa, & Whitaker, 
2001), supports the hypothesis that the PFC may be impaired in PTSD. 
 
 
Figure 1.4: Diagram showing the location of the PFC and its afferent projections from the locus 
coeruleus (LC), dorsal raphe nuclei (DRN), and the ventral tegmental area (VTA).  Efferents (not 
shown) include projections to the hippocampus (HIP), amygdala (AMG), thalamus (TH), and 







 Since PTSD has a high comorbidity with other psychiatric conditions, there are many 
drugs available that mental health providers prescribe to manage symptoms.  Treatment for 
PTSD directly, however, is comprised of only two drugs that are Food and Drug Administration 
(FDA) approved: the SSRIs sertraline and paroxetine (Roman, 2010; Sullivan & Neria, 2009).  
Although there have been studies that demonstrated some improvement in PSTD symptoms with 
the use of SSRIs, they are generally regarded as only moderately effective as a first-line therapy 
and even less so in combat-related PTSD (Tawa & Murphy, 2013).  Recent research found that 
efficacy rates of SSRIs in PTSD therapy rarely reached 60%, and less than 20-30% achieved full 
remission (Berger et al., 2009).  
 Based on their mechanism of action, SSRIs should increase 5-HT levels and attenuate 
many of the detrimental effects of lowered 5-HT.  This concept has proven effective in the 
treatment of depression (Doogan & Caillard, 1992; Miller et al., 1998).  In PTSD, however, 
results are less promising.  In a popular study by Davidson et al. which was a part of the FDA 
approval process for sertraline use in PTSD, they demonstrated decreased severity of symptoms 
and an overall increase in functioning in the PTSD patients vs. controls (Davidson, Rothbaum, 
van der Kolk, Sikes, & Farfel, 2001).  The results were achieved with multiple investigator- and 
self-rated assessments.  This study, however, had uneven gender distribution (84% female), 
racial distribution (83% white), and traumatic event distribution (64% physical or sexual assault).  
The effectiveness of sertraline, therefore, may be limited to a certain demographic and type of 
incident.  The data showed a 45% increase in symptom improvement in the treatment group, but 
also a 36% increase in symptom improvement in the placebo group.  Taken together, the 




addition, there were no physiological measures in the study that could analyze actual 
neurotransmitter modulation during treatment.  This information could be critical in determining 
the true efficacy of SSRIs as neurotransmitter changes are not mutually exclusive events.   
1.6 ANIMAL MODELS OF PTSD 
 Most of the current PTSD research is focused on human patients, which has its 
advantages and disadvantages.  The advantages are self-evident, but disadvantages include the 
variable backgrounds among patients, the type of stressful event (e.g., combat, rape, kidnapping, 
etc.), reduced experimental control in treatment studies, and the inability to determine baseline 
physiological data before PTSD developed.  An animal model mitigates those variables, but it 
also has drawbacks.  True PTSD is a human disorder that is diagnosed primarily through the 
verbal and written responses of the individual, so there is a certain amount of extrapolation 
necessary with animal models.  It is impossible to ask an animal how they are feeling or if they 
have persistent memories of a traumatic event.  Devices such as the elevated plus-maze, fear-
conditioning system, or Morris water maze are thus employed to ascertain anxiety changes vs. 
control animals.  Animal models provide excellent experimental control and negate many of the 
physiological and ethical barriers encountered in human PTSD research.  There are multiple 
animal models used in anxiety disorder research with varied approaches and methods.  Current 
models include inescapable foot shock (Rudy, Huff, & Matus-Amat, 2004), restraint stress 
(Vyas, Mitra, Shankaranarayana Rao, & Chattarji, 2002), social defeat (Huhman, 2006), and 
maternal separation (Diehl et al., 2012), among others.  Many of these models have been shown 
to be effective for establishing depression and/or fear conditioning, but not necessarily PTSD.  
Although a single traumatic event can cause PTSD in humans, the persistent stress of normal 




employ a single stressful event may simply be causing a temporary fear response that subsides 
after pertinent anxiety testing.  When certain methods such as social instability and additional 
stressors are combined, however, the results tend to bear more of a resemblance to human PTSD 
(Saavedra-Rodriguez & Feig, 2013).  For our experiments, it was important to select an animal 
model of PTSD that matched, as closely as possible, the behavioral, psychological, and 
physiological elements of PTSD in humans.  The predator exposure/psychosocial stress model 
by Zoladz et al., (Figure 1.5) possesses both predictive and construct validity, meaning the model 
is sensitive to clinically effective pharmacologic agents and the rationale underlying the model 
displays similarities to human PTSD (Bourin, Petit-Demouliere, Dhonnchadha, & Hascoet, 
2007).  The model demonstrates three hallmark features of PTSD: hormonal abnormalities, a 
long-lasting traumatic memory, and persistent anxiety (Zoladz, Conrad, Fleshner, & Diamond, 
2008; Zoladz, Fleshner, & Diamond, 2012). 
 In the predator exposure/psychosocial stress model, PTSD rats were individually isolated 
in cylindrical, Plexiglas containers and canned cat food was smeared on the outside of the 
cylinders.  The cylinders prevented direct contact with the cats, and the cat food induced 
movement in the cats.    Rats were then placed in a stainless steel cage consisting of a solid metal 
floor with a hinged, metal rod door, with a cat for one hour.  The first cat exposure was 
conducted during the light cycle (0700-1900).  Ten days later, a second cat exposure was 
conducted during the dark cycle (1900-0700).  In addition, the rats were subjected to 
psychosocial stress by changing their cage cohort daily.  The predator exposure/psychosocial 









Figure 1.5: Pictures showing the rat enclosed in the Plexiglas cylinder (top) and inside the cage 
with the cat during the predator exposure (bottom).  Canned cat food was smeared on the outside 







Figure 1.6: Diagram showing the 31-day predator exposure/psychosocial stress regimen.  This 
model was also modified beyond 31 days including additional cat exposures and continued cage 
cohort changes during treatment phases.  The extended model was necessary to ensure any noted 
improvement was due to treatment and not natural subsiding of anxiety.     
 
1.7 ANXIETY TESTING 
 One of the diagnostic criteria for PTSD is hyperarousal, which includes an exaggerated 
startle response and heightened anxiety (American, 2013).  To measure anxiety levels, we used 
the elevated plus-maze (EPM).  Rodents have a natural tendency to explore novel environments, 
but open areas or alleys (without protective walls) invoke a greater fear and avoidance response 
(Montgomery, 1955).  The EPM is widely used as a measure to test fear or anxiety and has been 
extensively validated for use in rats (Korte & De Boer, 2003; Pellow, Chopin, File, & Briley, 
1985).  The EPM is a four-arm maze, shaped like a “plus” sign, that consists of two open arms 
and two closed arms (Figure 1.7).  The rats were placed in the middle of the maze and allowed to 




open spaces versus their desire to explore novel environments.  Entry into the open areas is 
associated with increased freezing behavior as well as increased plasma corticosterone 
levels, indicating heightened anxiety (Pellow et al., 1985).  Anxiogenic compounds or 
procedures can increase avoidance of the fear-provoking open arms, whereas anxiolytic 
compounds or procedures can increase open arm exploration (Pellow et al., 1985).  The primary 
criteria correlated with anxiety levels are total arm entries (overall ambulations) and the percent 
time spent in the open vs. closed arms.   
 
 
Figure 1.7: Photograph of the elevated plus-maze showing the two enclosed and two open arms.  
The overhead camera mounted on the tripod captured the animals’ movements onto each 
different arm and measured distance traveled, total arm entries, and the amount of time spent in 




1.8 STATEMENT OF THE PROBLEM AND SPECIFIC AIMS 
 PTSD is a serious condition that affects millions of people, and with the Middle Eastern 
conflicts drawing down and troops returning home, the numbers are likely to rise.  Although 
PTSD is fairly well characterized from a behavioral standpoint, we still know very little about 
the molecular mechanisms involved with its development.  There has been research exploring the 
HPA axis and glucocorticoids, neurotransmitters, the immune system, brain peptides, the SAM 
system, and many others.  Most of this research, however, has been conducted on human PTSD 
patients.  A major hurdle to that approach is making valid comparisons to control subjects.  Since 
PTSD is a psychiatric diagnosis involving both physiological and environmental elements, it is 
reasonable to state that there is simply too much variability between individual experiences to 
make legitimate comparisons.  An animal model of PTSD, however, enables us to control the 
process and make comparisons between PTSD and control groups that would otherwise be 
impossible in humans.  Another problem facing PTSD understanding is the lack of 
pharmacotherapies available.  Sertraline and paroxetine are the only drugs that are FDA 
approved for treating PTSD, but their effectiveness has been questionable.  These drugs work 
well for depression, but they do not seem to manage the anxiety element of PTSD.   
Recent evidence demonstrated certain inflammatory and oxidative stress components 
might play a role in PTSD development, but to what extent is unknown.  In addition, 
neurotransmitter modulation might also be implicated, but the mechanisms are poorly 
understood.  We hypothesized that inflammation, oxidative stress, and increased sympathetic 
drive due to heightened catecholamines might be key elements to PTSD progression.  We tested 
our hypothesis through a series of in vivo experiments using the predator exposure/psychosocial 
stress model of PTSD on rats.  In our first experiment, we sought to determine whether 




we examined how neurotransmitters were modulated in response to the PTSD model.  Once we 
obtained this information, we conducted additional experiments to analyze the effects of certain 
drugs on inflammation, oxidative stress, and neurotransmitters.  In our third experiment, we 
administered VA and measured its effects on our target molecules.  Our final experiment 
involved the SSRI sertraline, and we attempted to elucidate a possible mechanism explaining 
why its efficacy in PTSD is so poor.  The specific aims of this project were as follows: 
Aim 1: Determine which inflammatory and reactive oxygen components, if any, were up-
regulated in an animal model of PTSD. 
Aim 2: Analyze neurotransmitter modulation in an animal model of PTSD and describe 
possible mechanisms responsible.  
Aim 3: Evaluate the effects of VA, a non-traditional PTSD therapy, on inflammation, 
oxidative stress, and neurotransmitters. 
Aim 4: Investigate potential factors responsible for sertraline’s minimal effectiveness in 
treating PTSD.         
1.9 REFERENCES 
Akiba, Y., Cave, J. W., Akiba, N., Langley, B., Ratan, R. R., & Baker, H. (2010). Histone 
deacetylase inhibitors de-repress tyrosine hydroxylase expression in the olfactory bulb 
and rostral migratory stream. Biochem Biophys Res Commun, 393(4), 673-677. doi: 
10.1016/j.bbrc.2010.02.054 
American Psychiatric Association. (1980). Diagnostic and Statistical Manual of Mental 
Disorders (3rd ed.). Washington DC: APA. 
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental 
Disorders: DSM-5, 5th ed. Washington DC: APA. 
Arora, R. C., Fichtner, C. G., O'Connor, F., & Crayton, J. W. (1993). Paroxetine binding in the 
blood platelets of post-traumatic stress disorder patients. Life Sci, 53(11), 919-928.  
Ash, B. L., Zanatta, S. D., Williams, S. J., Lawrence, A. J., & Djouma, E. (2011). The galanin-3 
receptor antagonist, SNAP 37889, reduces operant responding for ethanol in alcohol-




Baker, D. G., West, S. A., Nicholson, W. E., Ekhator, N. N., Kasckow, J. W., Hill, K. K., . . . 
Geracioti, T. D., Jr. (1999). Serial CSF corticotropin-releasing hormone levels and 
adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J 
Psychiatry, 156(4), 585-588.  
Banks, W. A. (2005). Blood-brain barrier transport of cytokines: a mechanism for 
neuropathology. Curr Pharm Des, 11(8), 973-984.  
Benarroch, EE. (2009). The locus ceruleus norepinephrine system: functional organization and 
potential clinical significance. . Neurology, 73(20), 1699-1704.  
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. 
R., & Figueira, I. (2009). Pharmacologic alternatives to antidepressants in posttraumatic 
stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry, 33(2), 
169-180. doi: 10.1016/j.pnpbp.2008.12.004 
Bourin, M., Petit-Demouliere, B., Dhonnchadha, B. N., & Hascoet, M. (2007). Animal models of 
anxiety in mice. Fundam Clin Pharmacol, 21(6), 567-574. doi: 10.1111/j.1472-
8206.2007.00526.x 
Bracha, HS, Garcia-Rill, E, Mrak, RE, Skinner, R. (2005). Postmortem locus coeruleus neuron 
count in three American veterans with probable or possible war-related PTSD. The 
Journal of neuropsychiatry and clinical neurosciences 17(4), 503-509. doi: 
10.1176/appi.neuropsych.17.4.503 
Brady, K. T., Killeen, T. K., Brewerton, T., & Lucerini, S. (2000). Comorbidity of psychiatric 
disorders and posttraumatic stress disorder. J Clin Psychiatry, 61 Suppl 7, 22-32.  
Brunet, A., Akerib, V., & Birmes, P. (2007). Don't throw out the baby with the bathwater (PTSD 
is not overdiagnosed). Can J Psychiatry, 52(8), 501-502; discussion 503.  
Chrousos, G. P. (1995). The hypothalamic-pituitary-adrenal axis and immune-mediated 
inflammation. N Engl J Med, 332(20), 1351-1362. doi: 10.1056/NEJM199505183322008 
Chrousos, G. P., & Gold, P. W. (1992). The concepts of stress and stress system disorders. 
Overview of physical and behavioral homeostasis. JAMA, 267(9), 1244-1252.  
Cohen, H., & Yehuda, R. (2011). Gender differences in animal models of posttraumatic stress 
disorder. Dis Markers, 30(2-3), 141-150. doi: 10.3233/DMA-2011-0778 
Covington, H. E., 3rd, Maze, I., LaPlant, Q. C., Vialou, V. F., Ohnishi, Y. N., Berton, O., . . . 
Nestler, E. J. (2009). Antidepressant actions of histone deacetylase inhibitors. J Neurosci, 
29(37), 11451-11460. doi: 10.1523/JNEUROSCI.1758-09.2009 






Dansie, E. J., Heppner, P., Furberg, H., Goldberg, J., Buchwald, D., & Afari, N. (2012). The 
comorbidity of self-reported chronic fatigue syndrome, post-traumatic stress disorder, 
and traumatic symptoms. Psychosomatics, 53(3), 250-257. doi: 
10.1016/j.psym.2011.08.007 
Davidson, J. R., Hughes, D., Blazer, D. G., & George, L. K. (1991). Post-traumatic stress 
disorder in the community: an epidemiological study. Psychol Med, 21(3), 713-721.  
Davidson, J. R., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R., & Farfel, G. M. (2001). 
Multicenter, double-blind comparison of sertraline and placebo in the treatment of 
posttraumatic stress disorder. Arch Gen Psychiatry, 58(5), 485-492.  
De Bellis, M. D., Baum, A. S., Birmaher, B., Keshavan, M. S., Eccard, C. H., Boring, A. M., . . . 
Ryan, N. D. (1999). A.E. Bennett Research Award. Developmental traumatology. Part I: 
Biological stress systems. Biol Psychiatry, 45(10), 1259-1270.  
de Jong, J. T., Komproe, I. H., Van Ommeren, M., El Masri, M., Araya, M., Khaled, N., . . . 
Somasundaram, D. (2001). Lifetime events and posttraumatic stress disorder in 4 
postconflict settings. JAMA, 286(5), 555-562.  
de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., & van Kuilenburg, A. B. (2003). 
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem 
J, 370(Pt 3), 737-749. doi: 10.1042/BJ20021321 
Delamothe, T. (2005). Happiness. BMJ, 331(7531), 1489-1490. doi: 10.1136/bmj.331.7531.1489 
DeYoung, C. G., Hirsh, J. B., Shane, M. S., Papademetris, X., Rajeevan, N., & Gray, J. R. 
(2010). Testing predictions from personality neuroscience. Brain structure and the big 
five. Psychol Sci, 21(6), 820-828. doi: 10.1177/0956797610370159 
Diehl, L. A., Alvares, L. O., Noschang, C., Engelke, D., Andreazza, A. C., Goncalves, C. A., . . . 
Dalmaz, C. (2012). Long-lasting effects of maternal separation on an animal model of 
post-traumatic stress disorder: effects on memory and hippocampal oxidative stress. 
Neurochem Res, 37(4), 700-707. doi: 10.1007/s11064-011-0660-6 
Doogan, D. P., & Caillard, V. (1992). Sertraline in the prevention of depression. Br J Psychiatry, 
160, 217-222.  
Dubovsky, S. L. (1994). Beyond the serotonin reuptake inhibitors: rationales for the development 
of new serotonergic agents. J Clin Psychiatry, 55 Suppl, 34-44.  
Edmondson, D., & Cohen, B. E. (2013). Posttraumatic stress disorder and cardiovascular disease. 
Prog Cardiovasc Dis, 55(6), 548-556. doi: 10.1016/j.pcad.2013.03.004 
Elks, C. M., & Francis, J. (2010). Central adiposity, systemic inflammation, and the metabolic 




Elks, C. M., Mariappan, N., Haque, M., Guggilam, A., Majid, D. S., & Francis, J. (2009). 
Chronic NF-{kappa}B blockade reduces cytosolic and mitochondrial oxidative stress and 
attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol, 296(2), 
F298-305. doi: 10.1152/ajprenal.90628.2008 
Ezra, M. B. (2001). Earliest evidence of post-traumatic stress? Br J Psychiatry, 179, 467.  
Fendt, M., Fanselow, M. S., & Koch, M. (2005). Lesions of the dorsal hippocampus block trace 
fear conditioned potentiation of startle. Behav Neurosci, 119(3), 834-838. doi: 
10.1037/0735-7044.119.3.834 
Fisher, J. P., & Paton, J. F. (2012). The sympathetic nervous system and blood pressure in 
humans: implications for hypertension. J Hum Hypertens, 26(8), 463-475. doi: 
10.1038/jhh.2011.66 
Francis, G. S., Cohn, J. N., Johnson, G., Rector, T. S., Goldman, S., & Simon, A. (1993). Plasma 
norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival 
and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. 
Circulation, 87(6 Suppl), VI40-48.  
Ganguly, P. K., Dhalla, K. S., Innes, I. R., Beamish, R. E., & Dhalla, N. S. (1986). Altered 
norepinephrine turnover and metabolism in diabetic cardiomyopathy. Circ Res, 59(6), 
684-693.  
Garzon, D., Yu, G., & Fahnestock, M. (2002). A new brain-derived neurotrophic factor transcript 
and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's 
disease parietal cortex. J Neurochem, 82(5), 1058-1064.  
Geracioti, T. D., Jr., Baker, D. G., Ekhator, N. N., West, S. A., Hill, K. K., Bruce, A. B., . . . 
Kasckow, J. W. (2001). CSF norepinephrine concentrations in posttraumatic stress 
disorder. Am J Psychiatry, 158(8), 1227-1230.  
Geracioti, T. D., Jr., Jefferson-Wilson, L., Strawn, J. R., Baker, D. G., Dashevsky, B. A., Horn, 
P. S., & Ekhator, N. N. (2013). Effect of traumatic imagery on cerebrospinal fluid 
dopamine and serotonin metabolites in posttraumatic stress disorder. J Psychiatr Res, 
47(7), 995-998. doi: 10.1016/j.jpsychires.2013.01.023 
Glover, D. A., Powers, M. B., Bergman, L., Smits, J. A., Telch, M. J., & Stuber, M. (2003). 
Urinary dopamine and turn bias in traumatized women with and without PTSD 
symptoms. Behav Brain Res, 144(1-2), 137-141.  
Glover, E. M., Mercer, K. B., Norrholm, S. D., Davis, M., Duncan, E., Bradley, B., . . . 
Jovanovic, T. (2013). Inhibition of fear is differentially associated with cycling estrogen 
levels in women. J Psychiatry Neurosci, 38(5), 341-348. doi: 10.1503/jpn.120129 
Guggilam, A., Cardinale, J. P., Mariappan, N., Sriramula, S., Haque, M., & Francis, J. (2011). 




role for superoxide and nitric oxide. Basic Res Cardiol, 106(2), 273-286. doi: 
10.1007/s00395-010-0146-8 
Gupta, M. A. (2013). Review of somatic symptoms in post-traumatic stress disorder. Int Rev 
Psychiatry, 25(1), 86-99. doi: 10.3109/09540261.2012.736367 
Guzowski, J. F., Knierim, J. J., & Moser, E. I. (2004). Ensemble dynamics of hippocampal 
regions CA3 and CA1. Neuron, 44(4), 581-584. doi: 10.1016/j.neuron.2004.11.003 
Hasselmo, M. E. (1995). Neuromodulation and cortical function: modeling the physiological 
basis of behavior. Behav Brain Res, 67(1), 1-27.  
Hu, S., Peterson, P. K., & Chao, C. C. (1998). Kappa-opioid modulation of human microglial 
cell superoxide anion generation. Biochem Pharmacol, 56(3), 285-288.  
Huhman, K. L. (2006). Social conflict models: can they inform us about human 
psychopathology? Horm Behav, 50(4), 640-646. doi: 10.1016/j.yhbeh.2006.06.022 
Inslicht, S. S., Metzler, T. J., Garcia, N. M., Pineles, S. L., Milad, M. R., Orr, S. P., . . . Neylan, 
T. C. (2013). Sex differences in fear conditioning in posttraumatic stress disorder. J 
Psychiatr Res, 47(1), 64-71. doi: 10.1016/j.jpsychires.2012.08.027 
Keslacy, S., Tliba, O., Baidouri, H., & Amrani, Y. (2007). Inhibition of tumor necrosis factor-
alpha-inducible inflammatory genes by interferon-gamma is associated with altered 
nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. Mol 
Pharmacol, 71(2), 609-618. doi: 10.1124/mol.106.030171 
Kessels, R. P., de Haan, E. H., Kappelle, L. J., & Postma, A. (2001). Varieties of human spatial 
memory: a meta-analysis on the effects of hippocampal lesions. Brain Res Brain Res Rev, 
35(3), 295-303.  
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). 
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National 
Comorbidity Survey Replication. Arch Gen Psychiatry, 62(6), 593-602. doi: 
10.1001/archpsyc.62.6.593 
Kessler, R. C., Sonnega, A., Bromet, E., Hughes, M., & Nelson, C. B. (1995). Posttraumatic 
stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry, 52(12), 1048-
1060.  
Korte, S. M., & De Boer, S. F. (2003). A robust animal model of state anxiety: fear-potentiated 
behaviour in the elevated plus-maze. Eur J Pharmacol, 463(1-3), 163-175.  
Kozorovitskiy, Y., & Gould, E. (2004). Dominance hierarchy influences adult neurogenesis in 





Laboratory of Neuro Imaging. (2005). [Computer generated model of the rat hippocampus]. 
Retreived from http://loni.usc.edu/Research/Atlases/Data/rat/RatAtlasViewer.php  
Liberzon, I., Abelson, J. L., Flagel, S. B., Raz, J., & Young, E. A. (1999). Neuroendocrine and 
psychophysiologic responses in PTSD: a symptom provocation study. 
Neuropsychopharmacology, 21(1), 40-50. doi: 10.1016/S0893-133X(98)00128-6 
Lukaschek, K., Baumert, J., Kruse, J., Emeny, R. T., Lacruz, M. E., Huth, C., . . . Investigators, 
Kora. (2013). Relationship between posttraumatic stress disorder and type 2 diabetes in a 
population-based cross-sectional study with 2970 participants. J Psychosom Res, 74(4), 
340-345. doi: 10.1016/j.jpsychores.2012.12.011 
Magruder, K. M., Frueh, B. C., Knapp, R. G., Johnson, M. R., Vaughan, J. A., 3rd, Carson, T. 
C., . . . Hebert, R. (2004). PTSD symptoms, demographic characteristics, and functional 
status among veterans treated in VA primary care clinics. J Trauma Stress, 17(4), 293-
301. doi: 10.1023/B:JOTS.0000038477.47249.c8 
Malberg, J. E. (2004). Implications of adult hippocampal neurogenesis in antidepressant action. J 
Psychiatry Neurosci, 29(3), 196-205.  
McEwen, B. S., & Magarinos, A. M. (2001). Stress and hippocampal plasticity: implications for 
the pathophysiology of affective disorders. Hum Psychopharmacol, 16(S1), S7-S19. doi: 
10.1002/hup.266 
Milad, M. R., & Quirk, G. J. (2002). Neurons in medial prefrontal cortex signal memory for fear 
extinction. Nature, 420(6911), 70-74. doi: 10.1038/nature01138 
Miller, I. W., Keitner, G. I., Schatzberg, A. F., Klein, D. N., Thase, M. E., Rush, A. J., . . . 
Keller, M. B. (1998). The treatment of chronic depression, part 3: psychosocial 
functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry, 
59(11), 608-619.  
Mokuno, K., Ohtani, K., Suzumura, A., Kiyosawa, K., Hirose, Y., Kawai, K., & Kato, K. (1994). 
Induction of manganese superoxide dismutase by cytokines and lipopolysaccharide in 
cultured mouse astrocytes. J Neurochem, 63(2), 612-616.  
Montgomery, K. C. (1955). The relation between fear induced by novel stimulation and 
exploratory behavior. J Comp Physiol Psychol, 48(4), 254-260.  
Morgan, M. A., Romanski, L. M., & LeDoux, J. E. (1993). Extinction of emotional learning: 
contribution of medial prefrontal cortex. Neurosci Lett, 163(1), 109-113.  
Muldoon, M. F., Mackey, R. H., Williams, K. V., Korytkowski, M. T., Flory, J. D., & Manuck, 
S. B. (2004). Low central nervous system serotonergic responsivity is associated with the 
metabolic syndrome and physical inactivity. J Clin Endocrinol Metab, 89(1), 266-271.  
Nair, A. R., Boersma, L. J., Schiltz, L., Chaudhry, M. A., & Muschel, R. J. (2001). Paradoxical 




phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett, 
166(1), 55-64.  
Oosthuizen, F., Wegener, G., & Harvey, B. H. (2005). Nitric oxide as inflammatory mediator in 
post-traumatic stress disorder (PTSD): evidence from an animal model. Neuropsychiatr 
Dis Treat, 1(2), 109-123.  
Orr, S. P., Metzger, L. J., Lasko, N. B., Macklin, M. L., Peri, T., & Pitman, R. K. (2000). De 
novo conditioning in trauma-exposed individuals with and without posttraumatic stress 
disorder. J Abnorm Psychol, 109(2), 290-298.  
Paterlini, M., Zakharenko, S. S., Lai, W. S., Qin, J., Zhang, H., Mukai, J., . . . Gogos, J. A. 
(2005). Transcriptional and behavioral interaction between 22q11.2 orthologs modulates 
schizophrenia-related phenotypes in mice. Nat Neurosci, 8(11), 1586-1594. doi: 
10.1038/nn1562 
Peirson, A. R., & Heuchert, J. W. (2000). Correlations for serotonin levels and measures of 
mood in a nonclinical sample. Psychol Rep, 87(3 Pt 1), 707-716.  
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985). Validation of open:closed arm entries in 
an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods, 14(3), 149-
167.  
Peters, L., Issakidis, C., Slade, T., & Andrews, G. (2006). Gender differences in the prevalence 
of DSM-IV and ICD-10 PTSD. Psychol Med, 36(1), 81-89. doi: 
10.1017/S003329170500591X 
Preuss, T. M. (1995). Do rats have prefrontal cortex? The rose-woolsey-akert program 
reconsidered. J Cogn Neurosci, 7(1), 1-24. doi: 10.1162/jocn.1995.7.1.1 
Preuss, T. M., & Goldman-Rakic, P. S. (1991). Myelo- and cytoarchitecture of the granular 
frontal cortex and surrounding regions in the strepsirhine primate Galago and the 
anthropoid primate Macaca. J Comp Neurol, 310(4), 429-474. doi: 
10.1002/cne.903100402 
Quirk, G. J., Russo, G. K., Barron, J. L., & Lebron, K. (2000). The role of ventromedial 
prefrontal cortex in the recovery of extinguished fear. J Neurosci, 20(16), 6225-6231.  
Roman, M. (2010). Treatment of post traumatic stress disorders: part I. Issues Ment Health Nurs, 
31(4), 302-303. doi: 10.3109/01612841003642741 
Rothbaum, B. O., Kozak, M. J., Foa, E. B., & Whitaker, D. J. (2001). Posttraumatic stress 
disorder in rape victims: autonomic habituation to auditory stimuli. J Trauma Stress, 
14(2), 283-293. doi: 10.1023/A:1011160800958 
Rudy, J. W., Huff, N. C., & Matus-Amat, P. (2004). Understanding contextual fear conditioning: 





Saavedra-Rodriguez, L., & Feig, L. A. (2013). Chronic social instability induces anxiety and 
defective social interactions across generations. Biol Psychiatry, 73(1), 44-53. doi: 
10.1016/j.biopsych.2012.06.035 
Salminen, A., Ojala, J., Kaarniranta, K., & Kauppinen, A. (2012). Mitochondrial dysfunction and 
oxidative stress activate inflammasomes: impact on the aging process and age-related 
diseases. Cell Mol Life Sci, 69(18), 2999-3013. doi: 10.1007/s00018-012-0962-0 
Sapru, Hreday N.; Siegel, Allan (2007). Essential Neuroscience. Hagerstown, MD: Lippincott 
Williams & Wilkins. 
Sharma, R. P., Grayson, D. R., & Gavin, D. P. (2008). Histone deactylase 1 expression is 
increased in the prefrontal cortex of schizophrenia subjects: analysis of the National 
Brain Databank microarray collection. Schizophr Res, 98(1-3), 111-117. doi: 
10.1016/j.schres.2007.09.020 
Sondergaard, H. P., Hansson, L. O., & Theorell, T. (2004). The inflammatory markers C-reactive 
protein and serum amyloid A in refugees with and without posttraumatic stress disorder. 
Clin Chim Acta, 342(1-2), 93-98. doi: 10.1016/j.cccn.2003.12.019 
Southwick, S. M., Paige, S., Morgan, C. A., 3rd, Bremner, J. D., Krystal, J. H., & Charney, D. S. 
(1999). Neurotransmitter alterations in PTSD: catecholamines and serotonin. Semin Clin 
Neuropsychiatry, 4(4), 242-248. doi: 10.153/SCNP00400242 
Strange, B., & Dolan, R. (1999). Functional segregation within the human hippocampus. Mol 
Psychiatry, 4(6), 508-511.  
Sullivan, G. M., & Neria, Y. (2009). Pharmacotherapy of PTSD: Current Status and 
Controversies. Psychiatr Ann, 39(6), 342-347. doi: 10.3928/00485713-20090515-01 
Tawa, J., & Murphy, S. (2013). Psychopharmacological treatment for military posttraumatic 
stress disorder: an integrative review. J Am Assoc Nurse Pract, 25(8), 419-423. doi: 
10.1111/1745-7599.12016 
Tong, X., Yin, L., & Giardina, C. (2004). Butyrate suppresses Cox-2 activation in colon cancer 
cells through HDAC inhibition. Biochem Biophys Res Commun, 317(2), 463-471. doi: 
10.1016/j.bbrc.2004.03.066 
Trimble, M.D. (1985). Post-traumatic Stress Disorder: History of a concept. Trauma and its 
wake: The study and treatment of Post-Traumatic Stress Disorder (C. R. Figley ed.). 
New York: Brunner/Mazel. 
Uemura, K., Iguchi, A., Yatomi, A., Miura, H., Honmura, A., Yanase, M., & Sakamoto, N. 
(1989). Involvement of the hippocampus in central nervous system-mediated 





Uylings, H. B., Groenewegen, H. J., & Kolb, B. (2003). Do rats have a prefrontal cortex? Behav 
Brain Res, 146(1-2), 3-17.  
van Praag, H., Christie, B. R., Sejnowski, T. J., & Gage, F. H. (1999). Running enhances 
neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci U S A, 
96(23), 13427-13431.  
van Praag, H., Schinder, A. F., Christie, B. R., Toni, N., Palmer, T. D., & Gage, F. H. (2002). 
Functional neurogenesis in the adult hippocampus. Nature, 415(6875), 1030-1034. doi: 
10.1038/4151030a 
Vyas, A., Mitra, R., Shankaranarayana Rao, B. S., & Chattarji, S. (2002). Chronic stress induces 
contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J 
Neurosci, 22(15), 6810-6818. doi: 20026655 
Williams, E., Stewart-Knox, B., Helander, A., McConville, C., Bradbury, I., & Rowland, I. 
(2006). Associations between whole-blood serotonin and subjective mood in healthy 
male volunteers. Biol Psychol, 71(2), 171-174. doi: 10.1016/j.biopsycho.2005.03.002 
Wilson, C. B., McLaughlin, L. D., Nair, A., Ebenezer, P. J., Dange, R., & Francis, J. (2013). 
Inflammation and oxidative stress are elevated in the brain, blood, and adrenal glands 
during the progression of post-traumatic stress disorder in a predator exposure animal 
model. PLoS One, 8(10), e76146. doi: 10.1371/journal.pone.0076146 
Wilson, C. B., McLaughlin, L. D., Nair, A., Ebenezer, P. J., Dange, R., & Francis, J. (2014). 
Predator exposure/psychosocial stress animal model of post-traumatic stress disorder 
modulates neurotransmitters in the rat hippocampus and prefrontal cortex. PLoS One, 
9(2), e89104. doi: 10.1371/journal.pone.0089104 
Yang, Y., & Raine, A. (2009). Prefrontal structural and functional brain imaging findings in 
antisocial, violent, and psychopathic individuals: a meta-analysis. Psychiatry Res, 174(2), 
81-88. doi: 10.1016/j.pscychresns.2009.03.012 
Yehuda, R. (2009). Status of glucocorticoid alterations in post-traumatic stress disorder. Ann N Y 
Acad Sci, 1179, 56-69. doi: 10.1111/j.1749-6632.2009.04979.x 
Yehuda, R., Southwick, S., Giller, E. L., Ma, X., & Mason, J. W. (1992). Urinary catecholamine 
excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis, 
180(5), 321-325.  
Zoladz, P. R., Conrad, C. D., Fleshner, M., & Diamond, D. M. (2008). Acute episodes of 
predator exposure in conjunction with chronic social instability as an animal model of 
post-traumatic stress disorder. Stress, 11(4), 259-281. doi: 10.1080/10253890701768613 
Zoladz, P. R., Fleshner, M., & Diamond, D. M. (2012). Psychosocial animal model of PTSD 
produces a long-lasting traumatic memory, an increase in general anxiety and PTSD-like 






INFLAMMATION AND OXIDATIVE STRESS ARE ELEVATED IN THE BRAIN, 
BLOOD, AND ADRENAL GLANDS DURING THE PROGRESSION OF POST-




 Post-Traumatic Stress Disorder (PTSD) is an anxiety disorder that can develop in 
response to real or perceived life-threatening situations.  According to the Diagnostic and 
Statistical Manual of Mental Disorders IV-Text Revision (DSM-IV-TR), a diagnosis of PTSD 
necessitates exposure to a life-threatening event, intrusive recollections of the event, avoidance 
of associated stimuli and numbing of general responsiveness, hyperarousal not present before the 
trauma, and a significant social impairment.  All of these symptoms must also persist for at least 
30 days (American Psychiatric Association, 2013).  To date, no definitive diagnostic biomarkers 
have been identified for PTSD.  Recent research, however, points toward physiological 
abnormalities in the brain, hypothalamic-pituitary-adrenal (HPA) axis, and immune system that 
may be responsible for the psychological manifestations of the disorder (Liberzon, Abelson, 
Flagel, Raz, & Young, 1999; Oosthuizen, Wegener, & Harvey, 2005; Sondergaard, Hansson, & 
Theorell, 2004).  Many chronic conditions such as hypertension, heart failure, and metabolic 
syndrome perpetuate in a state of increased inflammation and oxidative stress, exacerbating their 
pathophysiology (Cardinale et al., 2010; Elks & Francis, 2010; Guggilam et al., 2011).  We 
hypothesize that similar physiological mechanisms may play a role in PTSD development.   
• This chapter previously appeared as C. Brad Wilson, Leslie D. McLaughlin, Anand R. 
Nair, Philip J. Ebenezer, Rahul Dange, and Joseph Francis. Inflammation and oxidative 
stress are elevated in the brain, blood, and adrenal glands during the progression of post-
traumatic stress disorder in a predator exposure animal model, PLoS One 8(10): e76146. 






 Exposure to psychologically traumatic events, such as those experienced during combat 
or other situations posing a legitimate threat to safety and survival, place individuals at 
significant risk for developing PTSD.  A growing body of evidence suggests that exposure to 
traumatic stressors and subsequent psychological trauma may result in increased morbidity and 
premature demise of patients.  Much of the data available suggest traumatic exposure and 
subsequent PTSD may lead to increased incidence of cardiovascular disease, diabetes, chronic 
fatigue syndrome, and other conditions (Dansie et al., 2012; Edmondson & Cohen, 2013; Gupta, 
2013; Lukaschek et al., 2013).  Most of these diseases have detrimental inflammatory 
components that may exacerbate their progression.  Inflammation is a critical component of the 
immune response, but acute and chronic inflammation can damage cellular mechanisms.  
Stressful events affect the immune system by reducing the cellular response to mitogen 
stimulation, decreasing production of natural killer cell activity and altering levels of cytokines.  
Cytotoxic T lymphocytes, which regulate the balance between Th1 and Th2 cells, are altered by 
stress leading to a Th2 dominant response, resulting in an unrestrained production of pro-
inflammatory cytokines (PICs).  These PICs, especially the interleukins, have been shown to 
play an important role in modulating disease processes.  An important and detrimental 
consequence of increased cytokine production is the induction of nitric oxide (NO) and reactive 
oxygen species (ROS) (Hu, Peterson, & Chao, 1998; Mokuno et al., 1994).    
 Elevated levels of PICs and ROS can cause cell death and tissue damage, although the 
cellular mechanisms responsible for initiating these processes during the stress response have 
remained poorly understood.  In addition to leukocytic responses, PIC upregulation may also be 
due to the activation of inflammasomes (Salminen, Ojala, Kaarniranta, & Kauppinen, 2012).  




(PRRs) such as Toll-like receptors (TLRs) and NOD (nucleotide oligomerization domain)-like 
receptors (NLRs).  When the inflammasome complex is activated, it cleaves pro-caspase-1 into 
its active form, which results in, among other things, the production of PICs and initiates the 
inflammatory response.  When proliferation of PICs exceeds the ability of local cellular receptors 
to utilize them in autocrine or paracrine functions, they become blood-borne.  These cytokines 
can then be transported across the blood-brain barrier (Banks, 2005), where they activate 
microglial cells and induce the production of more cytokines.  The process results in a positive 
feedback loop, which can become self-sustaining and cause systemic organ dysfunction.  
Research from our lab has demonstrated the damaging effects of PICs when quantities reach 
uncontrolled levels.  We have also shown that blocking certain downstream transcription factors 
and gene modifiers of these cytokines reduces oxidative stress, inflammation, and associated 
damage in hypertension, heart failure (HF), and metabolic syndrome (MetS) (Elks & Francis, 
2010; Elks et al., 2009; Guggilam et al., 2011).  In light of this information, this study 
investigates whether oxidative stress and inflammation increase in the brain, adrenal glands, and 
systemic circulation during the progression of PTSD using a predator exposure/psychosocial 
stress animal model.   
2.2 MATERIALS AND METHODS 
Ethics Statement 
 This study was carried out in strict accordance with the recommendations of the Institute 
for Laboratory Animal Research’s 2011 Guide for the Care and Use of Laboratory Animals, 
under the auspices of an animal care and use protocol approved by the Louisiana State 






 Naïve adult male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) were used 
in all experiments.  The rats were the same age (12 weeks) and approximately the same weight 
(±15g) upon delivery.  Rats were pair-housed in standard plastic microisolator cages and had 
access to food and water ad libitum.  The cages were maintained in ventilated racks (racks hold 
eight cages vertically and five horizontally) and each cage was randomly assigned to a specific 
rack location to ensure groups were evenly distributed.  The vivarium room was kept on a 12-
hour light/dark cycle (0700-1900), room temperature was maintained at 20±1ºC, and humidity 
ranged from 23-42%.  After a one-week acclimation period, the mean weight of all rats was 
347.9g ± 4.5.  Two cats, one male and one female (Harlan Laboratories, Indianapolis, IN (male), 
and Tulane University, New Orleans, LA (female)) were used for all predator exposures.  Cats 
were seven and ten years old, respectively.  They were housed in an open room (15’ x 15’) in the 
vivarium with access to food, water, and enrichment devices ad libitum.  The cat room was on 
the same light/dark cycle and maintained at similar temperature and humidity as the rat room.          
Stress Induction 
 Following the acclimation period, rats were brought to the laboratory and under 
isoflurane anesthesia were weighed, ear-tagged, tail-marked (ear tag number written on tail for 
easy identification), and 250-500µL of blood was drawn from either the tail or lateral saphenous 
vein.  The rats were then randomly assigned to the “PTSD” or “control” group and returned to 
the vivarium for 24 hours.  The following day, PTSD rats were started on a predator 
exposure/psychosocial stress regimen, published and validated by Zoladz, et al., designed to 
produce a pre-clinical PTSD that closely mimics signs and symptoms seen in human patients 




isolated in cylindrical, Plexiglas containers (IITC Life Science, Inc., Woodland Hills, CA; tail 
cuff restraint containers for 400-600g rats and Kent Scientific, Torrington, CT; tail cuff restraint 
containers for 300-500g rats) and canned cat food (Friskies, Purina, St. Louis, MO) was smeared 
on the outside of the cylinders.  The cylinders prevented direct contact with the cats, and the cat 
food induced predatory movement in the cats.  Studies show a  moving cat invokes a greater fear 
response than a sedentary cat (Blanchard, Mast, & Blanchard, 1975).  Rats were then placed in a 
stainless steel holding cage (76cm x 76cm x 60cm) consisting of a solid metal floor with a 
hinged, metal rod door, with a cat for one hour.  The first cat exposure was conducted during the  
light cycle (0700-1900).  Ten days later, a second cat exposure was conducted during the dark 
cycle (1900-0700).  In addition to the cat exposures, starting on day one the rats were subjected 
to psychosocial stress by changing their cage cohort daily.  The cage cohort rotation was 
established prior to the start of the experiment, whereby each rat was never housed with the same 
rat on consecutive days and never housed with the same rat more than four times in a month.  
The predator exposure/psychosocial stress regimen was continued for 31 days.  After 31 days, 
PTSD and control group rats were euthanized via CO2 inhalation, perfused with a phosphate 
buffered vascular rinse solution, and the brains were removed.  The hippocampus, amygdala, and 
pre-frontal cortex (PFC) were dissected and flash-frozen in liquid nitrogen.  The thymus and 
adrenals glands were also removed, trimmed, weighed, and flash-frozen. 
Blood Collection 
 Approximately 250-500μL blood per animal was drawn from either the tail or lateral 
saphenous veins of rats in both groups, allowing a minimum of 24 hours between any 
consecutive blood draws to prevent anemia.  Anesthesia was induced in an isoflurane anesthesia 





Figure 2.1: The predator exposure/psychosocial stress model includes two cat exposures over a 
31-day period, combined with daily cage cohort changes.  In addition, blood was collected at 
three different time points and ROS levels were measured to determine oxidative stress within 
groups and between groups.  Anxiety was measured at the end of the stress regimen via EPM. 
The hind legs were shaved to allow access to the lateral saphenous veins.  Blood was collected 
using a heparinized 22g needle and microcentrifuge tube with 50µL of heparin.   
Petroleum jelly (Vaseline, Unilever, Englewood Cliffs, NJ) was applied at the puncture site when 
necessary to reduce clotting.  Alternatively, a lateral tail vein was used to collect blood after 
warming the tail in water and using the same gauge heparinized needle and microcentrifuge tube 
with 50µL of heparin.      
Elevated Plus-Maze 
 Rats were placed in the center of the elevated plus-maze (EPM) (EB-Instruments 
(Bioseb), Tampa Bay, FL) facing an open arm and allowed to roam freely for five minutes.  
Movement was monitored via an overhead camera and captured with a specifically designed 
software program (BioEPM3C, EB-Instruments, Tampa Bay, FL).  The primary measurements 
were the number of entries into each arm (total ambulations) and the total time spent in the open 




stand for the EPM was approximately 36” above the floor, and each arm measured 11 cm x 50 
cm.     
Growth Rates and Organ Weights 
 At the beginning of the experiment and after the 31-day stress induction period, rats were 
weighed to determine average growth rate/day of PTSD and control animals.  Following 
euthanasia, the adrenal glands and thymus were removed and weighed.  Those organs were 
chosen, as their structure and function have been shown to be adversely affected by stress 
(Gruver & Sempowski, 2008; Ulrich-Lai et al., 2006).  The adrenal weights were combined as 
one weight for each animal, and weight was expressed as mg/100g body weight.  Thymus weight 
was also expressed as mg/100g body weight. 
Corticosterone Analysis 
 Plasma corticosterone was measured using the DetectX Corticosterone ELISA (K-014-
H1, Arbor Assays, Ann Arbor, MI).  The samples were diluted and prepared as per the protocol, 
optical density was analyzed at 450nm with a plate reader (VersaMax, Molecular Devices, 
Hayward, CA), and a standard curve was created based on the concentrations in each sample.  
Electron Paramagnetic Resonance Spectroscopy 
 Total ROS, superoxide, and peroxynitrite were measured in whole blood (baseline, day 
12, and day 31), brain tissue (hippocampus and PFC), and the adrenal glands via electron 
paramagnetic resonance (EPR) as previously described (Mariappan, Elks, Fink, & Francis, 2009; 
Mariappan et al., 2010).  Blood was drawn from all rats at the beginning of the experiment 
(baseline), one day after the second cat exposure (day 12), and at the end of the predator 
exposure/psychosocial stress regimen (day 31).  Superoxide, peroxynitrite, and total ROS levels 




between groups (control vs. PTSD), to analyze oxidative stress during PTSD progression.  
Analysis of oxidative stress between groups was also compared with tissue collected following 
euthanasia.  Two different spin probes were used for EPR studies.  1-Hydroxy-3-
methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine(CMH) was used to measure tissue ROS and 
superoxide O2•−, and 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine(CPH) was used for 
measurement of tissue peroxynitrite (OONO−).  Briefly, pieces of tissue were incubated at 37°C 
with CMH (200 µM) for 30 min for ROS measurement; PEG-SOD (50 U/µL) for 30 min, then 
CMH (200 µM) for an additional 30 min for O2•− measurement; or CPH (500 µM) for 30 min 
for OONO− measurement.  Aliquots of incubated probe media were then taken in 50-µl 
disposable glass capillary tubes (Noxygen Science Transfer and Diagnostics) for determination 
of ROS, O2•−, or OONO− production.  All EPR measurements were performed using an EMX 
ESR eScan BenchTop spectrometer and super-high quality factor microwave cavity (Bruker 
Company, Germany).      
Real-Time PCR Analysis  
 Semi-quantitative real-time RT-PCR (n = 6/group) was used to determine the mRNA 
levels of IL-1β and the NALP3 inflammasome in the hippocampus.  The primer sequences used 
for real-time PCR are given (Table 2.1).  In brief, the rats were euthanized using CO2 inhalation, 
perfused with a phosphate buffered solution directly into the left ventricle, and the brains were 
quickly removed, dissected, and immediately flash-frozen in liquid nitrogen.  Total RNA 
isolation, cDNA synthesis and RT-PCR were performed as previously described (Agarwal, 
Welsch, Keller, & Francis, 2011).  Gene expression was measured by the ΔΔCT method and was 
normalized to GAPDH mRNA levels.  The data is presented as fold change of the gene of 




Table 2.1: Rat primers used for real-time RT-PCR. 
Gene Sense Antisense 
GAPDH agacagccgcatcttcttgt cttgccgtgggtagagtcat 
IL-1β cagaccactttggcagacttcact ggattcgttggctgttcggtcg 
NALP3 cagaaggcatgtgagaagca tgggtgtagcgtctgttgag 
IL, (Interleukin); NALP3, (NACHT, LRR, PYD domains containing protein 3); GAPDH, 
(Glyceraldehyde 3-phosphate dehydrogenase). 
 
Western Blot Analysis 
 Tissue homogenates from the hippocampus and PFC were subjected to Western Blot 
(WB) analysis (n =10/group) for the determination of protein levels of IL-1β, the NALP3 
inflammasome, and GAPDH. The extraction of protein and WB was performed as previously 
described (Agarwal et al., 2011).   The specific antibodies used included: IL-1β, NALP3, and 
GAPDH.  Primary antibodies were commercially obtained: IL-1β and GAPDH, 1:1000 dilution 
(SC-7884 and SC-20358 respectively, Santa Cruz Biotechnology, Santa Cruz, CA); and NALP3, 
1:1000 dilution (Biorbyt, San Francisco, CA).  Secondary antibodies were commercially 
obtained: anti-mouse, 1:500 dilution and anti-rabbit, 1:500 dilution (SC-2314 and SC-2004 
respectively, Santa Cruz Biotechnology, Santa Cruz, CA).  Immunoreactive bands were 
visualized using enhanced chemiluminescence (ECL Plus, Amersham), band intensities were 
quantified using ImageJ imaging software (NIH), and were normalized with GAPDH. 
Statistical Analysis 
 All data are presented as mean ± SEM.  Statistical analysis was done by one-way 
ANOVA with a Tukey’s post hoc test for multiple comparisons, and unpaired Student’s T-tests 
were used for two-column analyses.  P-values less than 0.05 were considered statistically 
significant.  Statistical analyses were performed using Prism (GraphPad Software, Inc, La Jolla, 






Growth Rates and Organ Weights 
 The PTSD group displayed a significantly diminished growth rate over the 31-day stress 
period, t(18) = 2.78, p < 0.05.  The same group also showed an increase in adrenal gland weight, 
t(18) = 5.66, p < 0.0001, and a decrease in thymus weight, t(18) = 4.81, p < 0.0001 relative to the 
control group (Table 2.2). 
Table 2.2: Growth rate and organ weights. 
Group Growth Rate (g/day) Adrenal Wt. (mg/100 
g.b.w.) 
Thymus Wt. (mg/100 
g.b.w.) 
Control (n=10) 1.72 (0.14) 10.73 (0.49) 80.24 (2.11) 
PTSD (n=10) 1.11* (0.17) 14.03* (0.32) 61.51* (3.28) 
*p < 0.05 relative to the control group. 
Plasma Corticosterone 
 The PTSD group displayed higher plasma corticosterone levels, t(14) = 2.24, p < 0.05 
relative to the control group (Figure 2.2). 
Elevated Plus-Maze Performance 
 The comparison of anxiety levels revealed the PTSD group spent considerably less time 
in the open vs. closed arms, t(18) = 3.88, p < 0.05.  Overall ambulations, however, were not  
affected as both groups were still relatively active inside the maze, t(18) = 0.34, p > 0.05 (Figure 
2.3).   
Oxidative Stress Analysis 
 To investigate the influence of the predator exposure/psychosocial stress regimen on 
oxidative stress/redox balance, we examined levels of superoxide, peroxynitrite, and total ROS 
in the hippocampus, PFC, and adrenal glands.  In the hippocampus, PFC, and adrenal glands, 





Figure 2.2: After 31 days of the predator exposure/psychosocial stress regimen, plasma 
corticosterone levels were higher in the PTSD group. Corticosterone was measured in plasma 
collected at the time of sacrifice and frozen prior to testing. Data are presented as ± SEM. *p < 
0.05 relative to the control group. 
 
three regions (p < 0.05).  Peroxynitrite in the PFC, however, did not reach significance (p > 0.05) 
(Figure 2.4).  In whole blood drawn at three different time points, superoxide levels were nearly 
identical at baseline, elevated at 12 days, and further elevated at 31 days relative to the control 
group (p < 0.05) (Figure 2.5).  Within-group comparison via repeated measures with the same 
animals of the PTSD group demonstrated superoxide levels were elevated (day 12 vs. baseline, p 
< 0.05) and further elevated (day 31 vs. day 12, p < 0.05).  Repeated measures of total ROS 
levels yielded similar results (Figure 2.5).  Repeated measures in the control group revealed 
superoxide and total ROS levels remained relatively unchanged ( p > 0.05).  
Brain Inflammatory Markers  
 To investigate the influence of the predator exposure/psychosocial stress regimen on 
inflammation, we examined mRNA (Figure 2.6) and protein (Figure 2.7) levels of IL-1β and 




elevated mRNA levels of IL-1β and NALP3 in all three regions.  In the hippocampus and PFC, 
protein for IL-1β and NALP3 was significantly higher in the PTSD group relative to controls.    
 
Figure 2.3: The PTSD group displayed significantly higher anxiety than the control group, as 
evidenced by their reluctance to spend time in the open arms of the EPM (A).  Total 
ambulations, however, were essentially equal between the two groups (B).  Anxiety on the EPM 
was tested within 24 hours of the final day of the 31-day stress regimen.  Data are presented as 
mean ± SEM.  ***p < 0.0001 relative to the control group. 
 
2.4 DISCUSSION 
 The present study sought to analyze specific pathophysiological mechanisms involved in 
the progression of PTSD by employing a predator exposure/psychosocial stress regimen.  Few 
animal models of PTSD exist, but the model by Zoladz et al. has been shown to cause heightened 
anxiety, exaggerated startle response, impaired cognition, and increased cardiovascular reactivity 
(Zoladz et al., 2012), all of which are common symptoms reported in humans with PTSD 
(Brewin, Andrews, & Valentine, 2000; Nemeroff et al., 2006).    Although animal models have 
their limitations, a major component missing from human PTSD research is the ability to 







Figure 2.4: Superoxide, peroxynitrite, and total ROS were all significantly elevated in the 
hippocampus (A) and adrenal glands (C) in the PTSD group.  Superoxide and total ROS were 
also elevated in the pre-frontal cortex (B) in the PTSD group, but peroxynitrite did not reach 
significance. All data are presented as mean ± SEM.  *p < 0.05, **p < 0.001, ***p < 0.0001 
relative to the control group. 
 
Figure 2.5: Superoxide (A) and total ROS (B) in the blood were measured between groups and 
within groups at three time points during the predator exposure/psychosocial stress regimen.  
Superoxide and total ROS were at approximately the same level for the PTSD and control groups 




mean ± SEM. *p < 0.05, ***p < 0.0001 relative to the control group. ##p < 0.001, ###p < 0.0001 
relative to the previous measurement of the same group. 
 
 
Figure 2.6: RT-PCR revealed IL-1β and NALP3 mRNA were significantly elevated in the 
hippocampus (A), PFC (B), and amygdala (C) in the PTSD group.  All data presented as mean ± 
SEM.  *p < 0.05 relative to the control group. 
 
We have successfully obtained such data with this model, and to our knowledge, we are the first 
to report the time-dependent progression of oxidative stress in the blood in PTSD animals.  In 
addition, we discovered damaging ROS in the hippocampus, PFC, and adrenal glands were also 
upregulated in response to the predator exposure/psychosocial stress regimen.  In the brain, 




elevated, demonstrating a neuroinflammatory component in PTSD.  Three novel and important 
findings emerged from this study.  First, oxidative stress and inflammation are upregulated in the 
 
Figure 2.7: Western Blot showed IL-1β and NALP3 protein in the hippocampus (A & B 
respectively) and PFC (C & D respectively) were significantly elevated in the PTSD group.  All 
data presented as mean ± SEM. *p < 0.05 relative to the control group. 
 
brain, namely the hippocampus, PFC, and amygdala, in response to psychological stress.  
Second, oxidative stress increases not only in the brain but also in the blood and adrenal glands, 
indicating PTSD may progress as a systemic condition involving multiple organ systems.  Last, 
and possibly most important, oxidative stress increases in the blood in a time-dependent manner 




 Most of the current PTSD research is focused on human patients, which has its 
advantages and disadvantages.  The advantages are self-evident, but disadvantages include the 
variable backgrounds among patients, the type of stressful event (e.g., combat, rape, kidnapping, 
etc.), reduced experimental control in treatment studies, and the inability to determine baseline 
physiological data before PTSD developed.  An animal model mitigates those variables, but as 
there are multiple animal models used in anxiety disorder research with varied approaches and 
methods, careful selection was necessary.  For our experiments, it was important to select an 
animal model of PTSD that matched, as closely as possible, the behavioral, psychological, and 
physiological elements of PTSD in humans.  The predator exposure/psychosocial stress model 
by Zoladz et al., possesses both predictive and construct validity, meaning the model is sensitive 
to clinically effective pharmacologic agents and the rationale underlying the model displays 
similarities to human PTSD (Bourin, Petit-Demouliere, Dhonnchadha, & Hascoet, 2007).  The 
model demonstrates three hallmark features of PTSD: hormonal abnormalities, a long-lasting 
traumatic memory, and persistent anxiety (Zoladz et al., 2012).          
 The roles of oxidative stress and inflammation in other pathological conditions including 
cardiovascular disease, diabetes mellitus, metabolic syndrome, and neurological diseases are 
well established (Agarwal et al., 2011; Alexopoulos et al., 2012; Elks & Francis, 2010; Pall & 
Satterlee, 2001).  Reactive oxygen species, or free radicals, have unpaired valence shell electrons 
and cause damage by oxidizing proteins, lipids, nucleic acids, and other cellular components.  
They are produced naturally via mitochondrial leakage, xanthine oxidase, and other pathways, 
and they are important in cell signaling, homeostasis, and host defense.  Under normal 
conditions, the body’s antioxidant mechanisms (e.g., superoxide dismutase, glutathione 




contrast, occurs when there is an imbalance between naturally occurring ROS and the body’s 
ability to convert them via antioxidants.  As ROS levels increase, they can cause DNA and 
protein oxidation, leading to tissue necrosis and upregulation of PICs (Pall & Satterlee, 2001).  
An important function of cytokines is to transmit information concerning inflammatory 
responses to the CNS (Chrousos, 2000; Dunn, 2000; McCann et al., 2000; Turnbull, Lee, & 
Rivier, 1998).  The CNS then participates in negative feedback regulation of the peripheral 
immune response by releasing pituitary hormones (adrenocorticotropic hormone [ACTH] and 
arginine vasopressin [AVP]) and increasing sympathetic drive.  Cortisol, AVP, and sympathetic 
nerve activity all act to suppress further peripheral production of cytokines, and cortisol also acts 
centrally to inhibit further production of corticotropin-releasing hormone (CRH).  When cytokine 
upregulation exceeds cellular usage, however, they may then be transported across the blood-
brain barrier (Banks, 2005), activate microglial cells, and induce the production of more 
cytokines.  The process becomes a positive feedback loop, which can become self-sustaining and 
result in severe organ dysfunction.  A proposed pathway by which this pathophysiology may 
occur is presented in Figure 2.8.  
 Recent research has sought to determine the pathophysiology of PTSD development and 
to identify diagnostic biomarkers, but progress has been slow on both endeavors.  Glucocorticoid 
derangements have been found to be variable (Baker et al., 1999; Liberzon et al., 1999; Yehuda, 
2009), hippocampus structural changes may or may not occur (Gilbertson et al., 2002; 
Oosthuizen et al., 2005), and studies have not been able to consistently delineate the specific 
roles of neurotransmitters (Sutherland & Davidson, 1994) in the disorder.  These conflicting 
reports indicate a need to explore other mechanisms possibly involved in PTSD 




many disease processes.  The involvement of oxidative stress and inflammation in PTSD, 
however, has only recently garnered attention.  Oosthuizen et al., reported that PTSD was  
 
 
Figure 2.8: Cytokine production in PTSD leads to upregulation of superoxide and nitric oxide, 
which bind to form the very potent oxidizer peroxynitrite. The resulting tissue damage sustains 
the positive feedback loop causing further detrimental effects. 
 
exacerbated by increased levels of NO and other ROS, causing cellular damage in the 
hippocampus (Oosthuizen et al., 2005).  Diehl et al., discovered DNA breakage, a sign of 
oxidative stress, in the hippocampus of rats subjected to stress via a maternal separation model 
(Diehl et al., 2012).  Our results demonstrate ROS and PICs are significantly upregulated during 
the progression of PTSD, indicating an increase in oxidative stress and inflammation in the brain, 
adrenals, and systemic circulation.  Whether or not the structural and functional damage these 
mechanisms may cause is contributory or a by-product of PTSD progression is yet to be 
determined.   
 Previous research regarding plasma glucocorticoid (cortisol in humans, corticosterone in 
rodents) levels in PTSD has been met with varied results.  Numerous studies have shown PTSD 
patients to have lower cortisol levels than the general population (Yehuda, 2009), but there have 
also been studies reporting no difference (Baker et al., 1999) or elevated levels (Liberzon et al., 
1999).  Cortisol is the primary hormone involved in the stress response, and its primary roles 




in a narrow therapeutic range, and hypercortisolism (Cushing’s syndrome) or hypocortisolism 
(Addison’s disease) both have deleterious effects.  In this experiment we found plasma 
corticosterone was elevated in the PTSD group vs. controls, which contrasted with the results of 
Zoladz et al., in this model (Zoladz et al., 2012).  In their experiment, lower baseline 
corticosterone levels were obtained in the undisturbed (non-dexamethasone/vehicle injected) 
group, whereas we measured corticosterone levels from plasma collected during euthanasia 
procedures immediately after the predator exposure/psychosocial stress regimen.  The difference 
in results underscores the rapid nature of glucocorticoid changes in response to even the slightest 
stressor, and may provide a rationale for often inconsistent results reported in animal models of 
PTSD.  Despite these differences, glucocorticoid abnormalities seem to play a legitimate role in 
PTSD progression, but to what extent still remains unanswered.   
 Chronic stress affects normal growth patterns, possibly due to increased HPA axis 
stimulation or other mechanisms acting in concert with upregulated glucocorticoids (Krahn, 
Gosnell, & Majchrzak, 1990).  The decrease noted in body weight growth rates in our rats may 
be attributable to endocrine abnormalities similar to those seen in human PTSD patients.  During 
traumatic or stressful events, there is a profound release of cortisol from the adrenal cortex 
(Bremner, 1999).  The hypothalamic-pituitary-adrenal (HPA) axis is activated by the 
hypothalamus via corticotropin releasing hormone (CRH) at the median eminence, which 
stimulates the release of ACTH from the anterior pituitary gland.  In turn, ACTH causes the 
release of cortisol from the adrenal cortex.  In non-PTSD individuals, cortisol exerts negative 
feedback control at the hypothalamus and pituitary, but recent research indicates PTSD patients 
may display aberrant endocrine profiles (Krystal & Neumeister, 2009; Vidovic et al., 2011).  One 




increased levels of CRH (Rohleder, Joksimovic, Wolf, & Kirschbaum, 2004; Stein, Yehuda, 
Koverola, & Hanna, 1997; Yehuda, Boisoneau, Lowy, & Giller, 1995).  Higher levels of CRH 
can inhibit feeding behavior, even in food-deprived animals (Krahn et al., 1990; Mazjoub, 2006).  
Increased adrenal gland weight may also be due to excessive glucocorticoid production without 
proper negative feedback from the hypothalamus, resulting in adrenal hypertrophy and 
hyperplasia (Ulrich-Lai et al., 2006).  The substantive decrease seen in thymus weight may be a 
result of increased oxidative stress or cortisol toxicity causing thymocyte apoptosis (Salgo & 
Pryor, 1996).             
 One of the diagnostic criteria for PTSD is hyperarousal, which includes an exaggerated 
startle response and heightened anxiety (American Psychiatric Association, 2013).  To measure 
anxiety levels, we used the elevated plus-maze (EPM).  Rodents have a natural tendency to 
explore novel environments, but open areas or alleys (without protective walls) invoke a greater 
fear and avoidance response (Montgomery, 1955).  The EPM is widely used as a measure to test 
fear or anxiety and has been extensively validated for use in rats (Korte & De Boer, 2003; 
Pellow, Chopin, File, & Briley, 1985).  The EPM is a four-arm maze, shaped like a “plus” sign, 
that consists of two open arms and two closed arms.  The premise behind the EPM is based on 
rodents’ natural aversion of open spaces versus their desire to explore novel environments.  
Entry into the open areas is associated with increased freezing behavior as well as increased 
plasma corticosterone levels, indicating heightened anxiety (Pellow et al., 1985).  Anxiogenic 
compounds or procedures can increase avoidance of the fear-provoking open arms, whereas 
anxiolytic compounds or procedures can increase open arm exploration (Pellow et al., 1985).  
The primary criteria correlated with anxiety levels are total arm entries (overall ambulations) and 




exposure/psychosocial stress regimen had a significant anxiogenic effect regarding time spent in 
the open vs. closed arms.  These findings demonstrate the model induced a marked increase in 
anxiety in the PTSD group vs. controls.  The lack of difference in overall ambulatory activity 
between the groups suggests activity level and anxiety may be independent measures in animal 
models of PTSD.     
 In summary, this study sought to determine if, as in many other disease processes, 
oxidative stress and inflammation increased during PTSD progression.  To answer this question, 
we used a predator exposure/psychosocial stress animal model of PTSD.  We validated stress 
induction via an EPM and also found plasma corticosterone levels to be elevated in the PTSD 
group.  In addition, growth rate and thymus weights were lower in the PTSD group, while 
adrenal gland weight was higher vs. controls.  Our findings indicate ROS and PICs are 
upregulated in the adrenal glands, circulating blood, and the areas of the brain associated with 
PTSD, indicating an increase in oxidative stress and inflammation as the disorder progresses.       
2.5 CONCLUSIONS 
 We utilized a predator exposure/psychosocial stress animal model of PTSD to 
demonstrate how oxidative stress and inflammation may play a key role in PTSD development.  
We found ROS and PICs were elevated in all three regions of the brain commonly associated 
with PTSD, indicating increased oxidative stress and inflammation.  In addition, oxidative stress 
and inflammation were elevated systemically, as evidenced by increased ROS and PICs in the 
adrenal glands and circulating blood.  We also noted a time-dependent nature of oxidative stress 
by analyzing whole blood drawn at different time points.  Levels of superoxide, peroxynitrite, 
and total ROS in the blood rose in an exponential nature throughout the stress period, while 




model established by Zoladz et al., (Zoladz et al., 2012) produced similar behavioral and 
physiological results, including a diminished growth rate, larger adrenal glands, a smaller 
thymus, and decreased time spent in the open arms of the EPM, confirming their results.  In 
contrast to their findings, we obtained higher post-stress corticosterone levels.  Their results, 
however, were obtained following a dexamethasone suppression test, whereas we tested plasma 
corticosterone on frozen blood collected immediately following euthanasia.  Overall, our results 
demonstrate the progressive nature of oxidative stress and inflammation during PTSD 
development and may provide new targets for pharmacologic and non-pharmacologic treatments.  
Future studies by our lab will seek to elucidate neurotransmitter modulation in response to the 
predator exposure/psychosocial stress regimen and the subsequent response to various treatment 
modalities.             
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PREDATOR EXPOSURE/PSYCHOSOCIAL STRESS ANIMAL MODEL OF POST-
TRAUMATIC STRESS DISORDER MODULATES NEUROTRANSMITTERS IN THE 
RAT HIPPOCAMPUS AND PREFRONTAL CORTEX 
 
3.1 INTRODUCTION 
 Post-Traumatic Stress Disorder (PTSD), recently reclassified as a trauma- and stressor-
related disorder, can develop in response to real or perceived life-threatening situations.  
According to the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5), a diagnosis 
of PTSD necessitates exposure to a life-threatening event, intrusive recollections of the event, 
avoidance of associated stimuli and numbing of general responsiveness, negative 
cognitions/mood, hyperarousal not present before the trauma, and a significant social 
impairment.  All of these symptoms must persist for at least 30 days and not be due to illness, 
medication, or substance abuse (American Psychiatric Association, 2013).  To date, no definitive 
diagnostic biomarkers have been identified for PTSD.  Recent research, however, points toward 
physiological abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis, sympathoadrenal 
medullary system, and immune system that may be implicated in the disorder (Liberzon et al., 
1999; Oosthuizen et al., 2005; Sondergaard et al., 2004; Wilson et al., 2013).  In the brain, 
neurotransmitter modulation may also play a critical role in PTSD development, and they 
continue to be the primary target for pharmacologic interventions.  It still remains unclear, 
however, exactly which neurotransmitters are up- or down-regulated during PTSD progression.       
• This chapter previously appeared as C. Brad Wilson, Philip J. Ebenezer, Leslie D. 
McLaughlin, and Joseph Francis. Predator exposure/psychosocial stress animal model of 
post-traumatic stress disorder modulates neurotransmitters in the rat hippocampus and 
prefrontal cortex, PLoS One 9(2): e89104. doi:10.1371/journal.pone.0089104. Open 





 A growing body of evidence suggests that exposure to traumatic stressors and 
psychological trauma may result in increased morbidity and mortality.  Much of the data 
available suggest traumatic exposure and subsequent PTSD may lead to increased incidence of 
cardiovascular disease, diabetes, chronic fatigue syndrome, and other conditions (Dansie et al., 
2012; Edmondson & Cohen, 2013; Gupta, 2013; Lukaschek et al., 2013), but the involvement of 
neurotransmitters has yet to be clearly delineated.  Serotonin (5-HT), for example, is a 
neurotransmitter responsible for many functions in the central nervous system (CNS) and 
peripheral organs.  5-HT influences aggression, arousal, sleep, anxiety, appetite, fear, learning, 
and other actions (Dubovsky, 1994).  5-HT is also the principle regulator of mood.  A study by 
Peirson et al. (Peirson & Heuchert, 2000) found lower platelet 5-HT2 receptor function was 
associated with depressed mood, while Williams et al. (Williams et al., 2006) demonstrated 
higher blood 5-HT levels were correlated with better mood.  An increased mood and overall 
sense of well-being has been shown, in both psychiatric and physical disorders, as protective and 
positively correlated with resiliency behavior (Delamothe, 2005).  PTSD research has 
demonstrated that 5-HT-uptake sites in platelets were lower in PTSD patients vs. controls 
(Arora, Fichtner, O'Connor, & Crayton, 1993).  Lower 5-HT has also been implicated in 
diminished physical health.  Muldoon et al. showed that a low prolactin response to 
fenfluramine, a drug that increases 5-HT levels, was associated with metabolic syndrome 
(Muldoon et al., 2004).   
 Norepinephrine (NE), a neurotransmitter principally affecting excitatory receptors, is also 
involved in the regulation of psychiatric and physical mechanisms.  Under normal conditions, 
NE is a principle component of the stress response, directly increasing heart rate and blood flow 




flight’ response.  Persistent noradrenergic activity, however, has been linked with negative 
outcomes in patients with congestive heart failure (CHF) (Francis et al., 1993) and diabetes 
(Ganguly, Dhalla, Innes, Beamish, & Dhalla, 1986).  Studies have also shown that individuals 
with PTSD have elevated cerebrospinal fluid (CSF) levels of NE (Geracioti et al., 2001) and 
noradrenergic hyperresponsiveness to various stimuli (Liberzon et al., 1999).  Dysregulation of 
noradrenergic neurons has also been associated with hyperarousal and intrusive recollections 
attributable to PTSD (Southwick et al., 1999).  
 Dopamine (DA), a neurotransmitter with primarily inhibitory effects, plays a major role 
in emotion and the reward system of the brain.  It optimally functions within a narrow range and 
dopaminergic hypo- or hyperactivity is implicated in both physical and psychiatric illnesses.  
Parkinson’s disease is characterized by a loss of dopaminergic neurons, and evidence suggests 
schizophrenia and psychosis are linked to elevated levels of DA (Paterlini et al., 2005).  DA may 
also have a role in PTSD, and studies have shown dopaminergic hyperactivity in male combat 
veterans (Yehuda, Southwick, Giller, Ma, & Mason, 1992), traumatized adult females (Glover et 
al., 2003), and abused children (De Bellis et al., 1999) with PTSD.  The dopamine metabolite 
homovanillic acid (HVA), often used as a diagnostic test for catecholamine-producing tumors of 
the adrenal glands, has also demonstrated aberrant levels in PTSD patients.  Geracioti et al. 
found HVA was significantly reduced in the CSF of combat-related PTSD patients immediately 
after viewing traumatic imagery (Geracioti et al., 2013).  Based on the previous research, the 
primary focus of this study was to determine how neurotransmitters were modulated in response 






3.2 MATERIALS AND METHODS 
Ethics Statement  
 This study was carried out in strict accordance with the recommendations of the Institute 
for Laboratory Animal Research’s 2011 Guide for the Care and Use of Laboratory Animals, 
under the auspices of an animal care and use protocol approved by the Louisiana State 
University Institutional Animal Care and Use Committee (Protocol Number: 12-067).  Upon 
completion of all PTSD-related experiments and in adherence with the approved protocol, the 
cats will be adopted out to approved families in the local area.       
Animals 
 Naïve adult male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) were used 
in all experiments.  The rats were the same age (12 weeks) and approximately the same weight 
(±15g) upon delivery.  Rats were pair-housed in standard plastic microisolator cages and had 
access to food and water ad libitum.  The cages were maintained in ventilated racks (racks hold 
eight cages vertically and five horizontally) and each cage was randomly assigned to a specific 
rack location to ensure groups were evenly distributed.  The vivarium room was kept on a 12-
hour light/dark cycle (0700-1900), room temperature was maintained at 20±1ºC, and humidity 
ranged from 23-42%.  After a one-week acclimation period, the mean weight of all rats was 
347.9g ± 4.5.  Two cats, one male and one female (Harlan Laboratories, Indianapolis, IN (male), 
and Tulane University, New Orleans, LA (female)) were used for all predator exposures.  Cats 
were seven and ten years old, respectively.  They were housed in an open room (15’ x 15’) in the 
vivarium with access to food, water, and enrichment devices ad libitum.  The cat room was on 






 Following the acclimation period, rats were brought to the laboratory and under 
isoflurane anesthesia were weighed, ear-tagged, tail-marked (ear tag number written on tail for 
easy identification), and 250-500µL of blood was drawn from either the tail or lateral saphenous 
vein.  The rats were then randomly assigned to the PTSD (n=10) or control (n=10) group and 
returned to the vivarium for 24 hours.  The following day, PTSD rats were started on a predator 
exposure/psychosocial stress regimen, published and validated by Zoladz et al., designed to 
produce a pre-clinical PTSD that closely mimics signs and symptoms seen in human patients 
(Zoladz, Conrad, Fleshner, & Diamond, 2008; Zoladz et al., 2012).  Briefly, PTSD rats were 
individually isolated in cylindrical, Plexiglas containers (IITC Life Science, Inc., Woodland 
Hills, CA; tail cuff restraint containers for 400-600g rats and Kent Scientific, Torrington, CT; tail 
cuff restraint containers for 300-500g rats) and canned cat food (Friskies, Purina, St. Louis, MO) 
was smeared on the outside of the cylinders.  The cylinders prevented direct contact with the 
cats, and the cat food induced predatory movement in the cats.  Studies show a  moving cat 
invokes a greater fear response than a sedentary cat (Blanchard et al., 1975).  Rats were then 
placed in a stainless steel holding cage (76cm x 76cm x 60cm) consisting of a solid metal floor 
with a hinged, metal rod door, with a cat for one hour.  The first cat exposure was conducted 
during the light cycle (0700-1900).  Ten days later, a second cat exposure was conducted during 
the dark cycle (1900-0700).  In addition to the cat exposures, starting on day one the rats were 
subjected to psychosocial stress by changing their cage cohort daily.  The cage cohort rotation 
was established prior to the start of the experiment, whereby each rat was never housed with the 
same rat on consecutive days and never housed with the same rat more than four times in a 




days, PTSD and control group rats were euthanized via decapitation and the brains were 
immediately removed.  The hippocampus, amygdala, and prefrontal cortex (PFC) were dissected 
and flash-frozen in liquid nitrogen.   
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY  
Preparation of Standard Solution 
 Neurotransmitter concentrations were detected using an Eicom HTEC 500 high 
performance liquid chromatography system.  The standard solutions of norepinephrine (NE; MW 
337.3), 3, 4- dihydroxyphenylacetic acid (DOPAC; MW 168.15), dopamine (DA; MW 158.17), 
5-hydroxyindoleacetic acid (5-HIAA; MW 218.68), homovanillic acid (HVA; MW 182.18), 5-
hydroxytryptamine (5-HT; MW 212.68) and isoproterenol (internal standard; MW 247.7), each 1 
ng/µL concentration, were prepared by serial dilution.  5-HT and 5-HIAA were dissolved in 
0.1M acetic acid including 1mg/mL EDTA and other salts were prepared in 0.1M hydrochloric 
acid including 1mg/mL EDTA.  These solutions were prepared and filtered through a 0.45µm 
centrifuge tube filter before injection into the HPLC system.  Different concentrations were 
injected by maintaining the volume of injection at 10µL in order to quantify sample values after 
authenticating the retention time of individual neurotransmitters. 
Preparation of Samples  
 Sample preparations from the experimental animals were carried out according to the 
procedure of Deyama et al. (Deyama et al., 2008).  Hippocampus and PFC tissue were weighed 
and dissected before homogenizing at 4º C with 0.2 M perchloric acid including 100μM EDTA-
2Na in a Teflon/glass homogenizer.  The homogenate was centrifuged at 4º C for 15 min at 
20,000 x g.  The supernatant was collected and filtered through a 0.45µm centrifuge tube filter 




HPLC–EC Detection of Neurotransmitters 
 The following working conditions were maintained in the HPLC system: isocratic 
elution; mobile phase (citrate buffer in methanol with EDTA and sodium octane sulfonate); 
Eicompak SC-3ODS (ID 3.0 X 100mm) column; flow rate 340 µL/min; graphite working 
electrode WE-3G (Gasket GS-25), (+750mV versus Ag/AgCl electrode); temperature 25°C.  The 
levels of neurotransmitters are expressed as pg/µg of wet tissue. 
Mobile phase  
 Citric acid monohydrate (8.84 g; mol wt. 210.14), and 3.10g of sodium acetate (mol. wt. 
82.03) in 800 ml of MilliQ Ultrapure fresh water (>18.2MΩ/cm) and 200ml of HPLC grade 
methanol were added and shaken well (magnetic stirrer not used).  EDTA (Dojindo Laboratories, 
USA, mol. wt. 372.24; 0.005g) and sodium octane sulfonate (Dojindo Laboratories, USA, and 
0.220 g) were added and shaken well. 
Western Blot 
 Tissue homogenates from the hippocampus and PFC were subjected to Western Blot 
(WB) analysis (n =10/group) for the determination of protein levels of the norepinephrine and 
dopamine rate-limiting enzyme tyrosine hydroxylase (TH), the 5-HT rate-limiting enzyme 
tryptophan hydroxylase (TPH), and GAPDH. The extraction of protein and WB was performed 
as previously described (Agarwal et al., 2011).   The specific antibodies used included: TH, TPH, 
and GAPDH.  Primary antibodies were commercially obtained: TH, 1:1000 dilution (AB-112, 
Abcam, Cambridge, MA.); TPH, 1:1000 dilution (AB-1541, Millipore, Billerica, MA.); 
GAPDH, 1:1000 dilution (SC-25778, Santa Cruz Biotechnology, Santa Cruz, CA).  Secondary 
antibodies were commercially obtained: anti-rabbit, 1:5000 dilution, anti-sheep, 1:5000 dilution 




Immunoreactive bands were visualized using enhanced chemiluminescence (ECL Plus, 
Amersham), band intensities were quantified using ImageJ imaging software (NIH), and they 
were normalized with GAPDH. 
Statistical Analysis 
 All data are presented as mean ± SEM.  Statistical analysis was done by Student’s T-Test 
or one-way ANOVA with a Tukey’s post hoc test. P-values less than 0.05 were considered 
statistically significant.  Statistical analyses were performed using Prism (GraphPad Software, 
Inc, La Jolla, CA; version 5.0). 
3.3 RESULTS 
Neurotransmitters and their metabolites were modulated in the hippocampus and PFC 
Table 3.1: Changes in the levels of biogenic amines and metabolites in the PFC and 
hippocampus after the 31-day predator exposure/psychosocial stress regimen.  Average 
concentration in pg/µg of wet tissue (±SEM) in the hippocampus (n=10 for both groups). 
 
5-HT: 5-hydroxytrypamine, HVA: homovanillic acid, NE: norepinephrine, DOPAC: 3,4-
Dihydroxyphenylacetic acid, DA: dopamine, 5-HIAA: 5-Hydroxyindoleacetic acid.  *p < 0.05, 
**p < 0.001, ***p < 0.0001 relative to the control group. 
 
Parameters Prefrontal Cortex Hippocampus 
 
5-HT 
Control 3250.2 ± 503.3 349.8 ± 34.0 
PTSD 2067.9 ± 148.2* 165.3 ± 14.9*** 
NE   
Control 421.5 ± 32.8 533.0 ± 64.6 
PTSD 671.6 ± 55.3** 1277 ± 172.3*** 
DA   
Control 1637.4 ± 226.7 545.3 ± 95.6 
PTSD 5640.1 ± 383.4*** 646.4 ± 74.5 
HVA   
Control 1419.6 ± 202.5 224.6 ± 19.3 
PTSD 1386.2 ± 119.9 128.7 ± 18.3** 
DOPAC   
Control 2446.8 ± 152.0 853.9 ± 114.4 
PTSD 4135.7 ± 371.6*** 1391.0 ± 27.9*** 
5-HIAA   
Control 1907.6 ± 253.4 976.1 ± 152.7 
PTSD 1525.2 ± 175.4 854.1 ± 63.6 




To investigate the influence of the predator exposure/psychosocial stress regimen on 
neurotransmitter modulation, we examined endogenous levels of biogenic amines and their 
metabolites in the hippocampus and PFC of control and PTSD animals using HPLC (Table 3.1).   
In the hippocampus, the levels of the tryptamine 5-HT and the DA metabolite HVA (Figure 
3.1A) were significantly lower in the PTSD group vs. controls, t(18) = 4.96, p < 0.0001 and t(18) 
= 3.61, p  < 0.05, respectively.  Conversely, the levels of the catecholamine NE and the DA 
metabolite DOPAC (Figure 3.1B) were significantly higher in the PTSD group, t(18) = 4.05, p <  
 
Figure 3.1: 5-HT and HVA were both significantly down-regulated (A), while NE and DOPAC 
were both significantly elevated (B), in the hippocampus in response to the predator 
exposure/psychosocial stress model.  All data are presented as mean ± SEM.  **p < 0.001, ***p 
< 0.0001 relative to the control group. 
 
0.001, and t(18) = 4.56, p < 0.001, respectively.  There were no significant changes noted in DA 
or 5-HIAA.  In the PFC, the tryptamine 5-HT was significantly lower, while the catecholamine 
NE was higher (Figure 3.2A), in the PTSD group vs. controls, t(18) = 2.25, p < 0.05, and t(18) = 
3.89, p < 0.001.  In addition, the levels of the catecholamine DA and the DA metabolite DOPAC 
(Figure 3.2B) were significantly higher in the PTSD group, t(18) = 8.99, p < 0.0001, and t(18) = 





Rate-limiting enzyme fluctuations confirmed neurotransmitter modulation 
 To verify the observed changes in neurotransmitter levels in the hippocampus and PFC, 
we performed Western Blots of the rate-limiting enzymes for dopamine and norepinephrine 
(tyrosine hydroxylase (TH)) and 5-HT (tryptophan hydroxylase (TPH)). In both the hippocampus 
t(6) = 5.00, p < 0.01 and PFC t(6) = 4.75, p < 0.01, TH was elevated in the PTSD group vs. 
controls (Figures 3.3A and 3.3C).  Conversely, TPH was significantly downregulated in the 
hippocampus t(6) = 2.14, p < 0.05 and PFC t(6) = 5.20, p < 0.01 in the PTSD group vs. controls 
(Figures 3.3B and 3.3D).   
3.4 DISCUSSION  
 The present study sought to analyze neurotransmitter modulation in the hippocampus and 
PFC of rats subjected to pre-clinical PTSD via a predator exposure/psychosocial stress regimen.  
A myriad of animal models of PTSD exist, but the model by Zoladz et al. has been shown to 
cause heightened anxiety, exaggerated startle response, impaired cognition, and increased 
cardiovascular reactivity (Zoladz et al., 2008; Zoladz et al., 2012), all of which are common 
symptoms reported in humans with PTSD (Brewin et al., 2000; Nemeroff et al., 2006).    
Although animal models have their limitations, a major component missing from human PTSD 
research is the ability to ascertain physiological data directly from specific brain regions 
immediately after a stressful event.   The majority of the human physiological data gathered in 
vivo are derived from CSF, blood, or urine, which may not accurately reflect neurotransmitter 
modulation in the brain and certainly cannot distinguish between changes in specific brain 
regions.  We have successfully obtained such data with this model, and to our knowledge, we are 





Figure 3.2: NE was elevated and 5-HT was down-regulated in the PFC in response to the 
predator exposure/psychosocial stress model (A).  In addition, DA, and DOPAC were also 
significantly elevated (B).  All data are presented as mean ± SEM.  *p < 0.05, **p < 0.001, ***p 
< 0.0001 relative to the control group. 
 
Figure 3.3: Tyrosine hydroxylase elevation in the PFC (A) and hippocampus (B) substantiated 
the findings of elevated levels of NE and DA, while down-regulated tryptophan hydroxylase in 
the PFC (C) and hippocampus (D) confirmed decreased levels of 5-HT.  All data are presented as 





and important findings emerged from this study.  First, the predator exposure/psychosocial stress 
regimen of pre-clinical PTSD produced measureable changes in neurotransmitters in the rat 
brain.  Second, and possibly most important, 5-HT decreased and NE increased in both the 
hippocampus and PFC, providing evidence that the neurotransmitters previously implicated in 
PTSD pathophysiology are in fact modulated in response to persistent stressors.  
 Human PTSD research has made significant advances, but certain undefined variables 
still exist.  Inconsistencies in patient backgrounds, types of stressful events (e.g., combat, rape, 
natural disasters, etc.), innumerable epigenetic differences, and the inability to obtain 
physiological data before PTSD development all present challenges.  An animal model mitigates 
these variables, but as there are multiple animal models used in PTSD research with varied 
approaches and methods, careful selection is necessary.  For our experiments, it was important to 
select an animal model of PTSD that matched, as closely as possible, the behavioral, 
psychological, and physiological elements of PTSD in humans.  The predator 
exposure/psychosocial stress model by Zoladz et al. possesses both predictive and construct 
validity, making the model sensitive to clinically effective pharmacologic agents and the 
rationale underlying the model displays similarities to human PTSD (Bourin et al., 2007).  This 
model demonstrates three hallmark features of PTSD: hormonal abnormalities, a long-lasting 
traumatic memory, and persistent anxiety (Zoladz et al., 2008; Zoladz et al., 2012).         
 The modulation of various neurotransmitters observed with the predator 
exposure/psychosocial stress model is in concert with many of the neurotransmitter changes seen 
in human PTSD patients (Arora et al., 1993; Geracioti et al., 2001; Geracioti et al., 2013; Yehuda 
et al., 1992).  Previous research has shown that stress blocks hippocampal long-term potentiation 




hippocampus, the primary region for spatial and long-term memory storage, expresses all of the 
5-HT receptor families and reflects the overall serotonergic functions relating to cognition and 
mood in this region (Berumen, Rodriguez, Miledi, & Garcia-Alcocer, 2012).  During stress, 
glucocorticoid production can reduce the excitability of hippocampal neurons, and 5-HT may 
have a protective effect against such damage by activating 5-HT1A receptors (Joca, Ferreira, & 
Guimaraes, 2007).  Persistent activation of the HPA axis and excessive production of 
glucocorticoids, however, may directly reduce hippocampal 5-HT levels and adversely affect 
normal serotonergic transmission, thus contributing to heightened fear, depressed mood, and 
reduced resilience.  The hippocampus also contains multiple NE receptors, which, when 
activated during stress, may contribute to the reinforcement of long-term memories (Jurgens et 
al., 2005).  In a study by Geracioti et al. involving male combat veterans with PTSD, CSF 
concentrations of NE were significantly higher vs. controls (Geracioti et al., 2001).  This finding 
could possibly explain why memories formed during extremely stressful events persist over time.  
Other evidence of catecholamine dysregulation in PTSD includes elevated urine catecholamine 
excretion, exaggerated biochemical responses to yohimbe, and clinical efficacy of adrenergic 
blockers (Southwick et al., 1999).  Noradrenergic modulation was also noted with previous 
experiments utilizing the predator exposure/psychosocial stress animal model and treatments 
with selective serotonin reuptake enhancers (SSRE), α2 agonists, and tricyclic antidepressants 
(Zoladz, Fleshner, & Diamond, 2013).  Although we found no significant difference in DA levels 
in the hippocampus, reduction of HVA level was consistent with current human PTSD research 
(Geracioti et al., 2013).  HVA is a downstream product of DA metabolism, and traumatic stress 
may impede CNS release of DA from the substantia nigra and ventral tegmental area (VTA) 




reducing metabolite concentration.  Another explanation may be that the majority of DA is 
directly converted to NE and not HVA, which also would further explain the marked increase in 
NE. 
 The PFC, responsible for executive functions such as consequences, drive, and social 
“control”, is highly innervated by serotonergic neurons from the raphe nuclei and also expresses 
an abundance of 5-HT receptors.  The serotonergic neurons and 5-HT receptors, specifically the 
5-HT1A and 5-HT2A receptors, are a key modulator of the PFC-amygdala corticolimbic circuit 
involved in threat and emotional responses (Fisher et al., 2011).  PTSD-related aberrancies in 
this serotonergic system may cause inappropriate or incomplete extinction of conditioned fear.  
The PFC also contains NE receptors and receives input from NE neurons from the locus 
coeruleus, which are activated during the stress response (Finlay, Zigmond, & Abercrombie, 
1995).  Pathogical or stress-related elevations of NE in the PFC, however, may inhibit working 
memory and performance (Zhang, Cordeiro Matos, Jego, Adamantidis, & Seguela, 2013).  
Current neuroimaging research indicates the PFC is hyporesponsive during symptomatic PTSD 
states and responsiveness is inversely proportional to symptom severity (Shin, Rauch, & Pitman, 
2006).  Whether marked elevations in NE directly or indirectly diminish PFC responsiveness and 
subsequent performance on cognitive emotional tasks remains unclear.  In contrast to unchanged 
DA levels in the hippocampus, DA levels were significantly increased in the PFC, which was 
similar to the CSF and urine DA elevations seen in humans with PTSD (De Bellis et al., 1999; 
Glover et al., 2003; Yehuda et al., 1992).  In a similar manner to NE, stress-related elevations of 
DA may also impair working memory and performance.  The PFC is densely innervated by 
dopaminergic neurons from the VTA, and dopamine release can be achieved via VTA or local 




stimulation of DA neurons caused a local release of DA in the PFC (Butts, Weinberg, Young, & 
Phillips, 2011).  These data support the theory that overstimulation of the HPA axis and the 
resulting elevation in glucocorticoid activity can directly modulate DA and possibly other 
neurotransmitters.            
3.5 CONCLUSIONS 
 We utilized a predator exposure/psychosocial stress animal model of PTSD to determine 
if neurotransmitters were modulated in the rat hippocampus and PFC.  We found that various 
neurotransmitters implicated in PTSD pathophysiology were altered in similar manners to those 
previously described in human PTSD research.  In addition, we determined that other 
neurotransmitters were differentially expressed in the hippocampus and PFC.  It would be an 
oversimplification, nonetheless, to presume that neurotransmitter modulation is the sole causal or 
resultant factor in PTSD development, as HPA axis, sympathoadrenal medullary pathway, and 
immune system alterations may also play an integral role in the pathophysiology of this complex 
disorder.  Our use of the model established by Zoladz et al., (Zoladz et al., 2008; Zoladz et al., 
2012) produced results consistent with current neurotransmitter levels obtained via CSF and 
urine analysis in humans, further validating the efficacy of the model.  Overall, our results 
demonstrate that there are CNS-specific modifications in neurotransmitter activity and 
expression in response to predator exposure/psychosocial stress.  Future studies by our lab will 
investigate neurotransmitter modulation in the hippocampus and PFC in response to FDA-
approved pharmacologic interventions and possibly provide insight into to why selective 
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VALPROIC ACID EFFECTS IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX 
IN AN ANIMAL MODEL OF POST-TRAUMATIC STRESS DISORDER 
 
4.1 INTRODUCTION 
 Post-Traumatic Stress Disorder (PTSD), an anxiety disorder recently reclassified as a 
trauma- and stressor-related disorder, can develop in response to real or perceived life-
threatening situations and results in a prolonged stress response (Yehuda, 2002).  According to 
the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5), a diagnosis of PTSD 
necessitates exposure to a traumatic event, intrusive recollections, avoidance of associated 
stimuli, negative cognitions/mood, hyperarousal, and a significant social impairment.  These 
symptoms must persist for at least 30 days and not be due to illness, medication, or substance 
abuse (American Psychiatric Association, 2013).  To date, no definitive diagnostic biomarkers 
have been identified for PTSD.  Current research, however, points toward physiological 
abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis, sympathoadrenal medullary 
system, immune system, and brain neurotransmitters that may be responsible for the progression 
of the disorder (Liberzon, Abelson, Flagel, Raz, & Young, 1999; Oosthuizen, Wegener, & 
Harvey, 2005; Sondergaard, Hansson, & Theorell, 2004; Wilson et al., 2014).  Many chronic 
conditions such as hypertension, heart failure, and metabolic syndrome perpetuate in a state of 
inflammation and oxidative stress (Cardinale et al., 2010; Elks & Francis, 2010; Guggilam et al., 
2011).  In PTSD, inflammation and oxidative stress also persist.   
• This chapter previously appeared as C. Brad Wilson, Leslie D. McLaughlin, Philip J. 
Ebenezer, Anand R. Nair, and Joseph Francis. Valproic Acid Effects in the Hippocampus 
and Prefrontal Cortex in an Animal Model of Post-Traumatic Stress Disorder, 
Behavioural Brain Research (2014), http://dx.doi.org/10.1016/j.bbr.2014.03.029.  It is 





Our lab recently demonstrated ROS and PICs were elevated in the brain and systemic circulation 
during PTSD progression (Wilson et al., 2013).       
 Inflammation is a critical component of the immune response, but chronic inflammation 
can damage cellular mechanisms.  There are a host of triggers initiating the inflammatory 
response, many of which are initiated via Toll-like receptor-4 (TLR4) and subsequent nuclear 
factor (NF)-κB activation.  Transcription by NF-κB requires DNA and chromatin remodeling, 
which enables access to the pertinent genomic sequences.  Gene expression is regulated via 
highly controlled acetylation/deacetylation of histone N-terminal tails, which either increases or 
decreases gene availability (de Ruijter, van Gennip, Caron, Kemp, & van Kuilenburg, 2003).  
Acetylation/deacetylation is accomplished by histone acetyltransferases (HAT) and histone 
deacetylases (HDAC), which enable and restrict genome access, respectively.  When oxidative 
stress and inflammation are increased, upregulated PICs can correspond with heightened HDAC 
activity and NF-κB transcription, resulting in perpetual PIC production (Keslacy, Tliba, 
Baidouri, & Amrani, 2007).  Although HDACs restrict access for transcription and should 
depress PIC production, the exact opposite may be the case.  The effects of HDAC inhibitors 
(HDACi) extend to non-histone proteins that are reversibly acetylated, which markedly affects 
their function (Nair, Boersma, Schiltz, Chaudhry, & Muschel, 2001; Tong, Yin, & Giardina, 
2004).  This functional shift means HDACs may actually enhance the inflammatory response.  In 
addition to histone modification, HDACs may also modulate neurotransmitters by modifying 
levels of pertinent rate-limiting enzymes (Sharma, Grayson, & Gavin, 2008).  For example, 
tyrosine hydroxylase, the rate-limiting enzyme for dopamine (DA) and norepinephrine (NE) 




effects of HDACi (Covington et al., 2009), possibly be due to epigenetic modifications of 
tryptophan hydroxylase, the rate-limiting enzyme for serotonin (5-HT) synthesis.       
 Currently, HDACi have proven beneficial as anticonvulsants and mood-stabilizers and 
have received attention as treatment for some forms of cancer (Alvarez-Breckenridge et al., 
2012).  They have also been shown to modify receptors and other neuronal cellular mechanisms 
that have a role in synaptic plasticity and learned behavior (Morris, Karra, & Monteggia, 2010).  
Research has demonstrated that administration of HDACi enhanced synaptic plasticity, dendritic 
growth, and the extinction of learned behavior in a drug-induced animal model (Malvaez, 
Sanchis-Segura, Vo, Lattal, & Wood, 2010).  A recent study revealed that the HDACi valproate 
enhances fear extinction (Heinrichs, Leite-Morris, Rasmusson, & Kaplan, 2013).  Since fear 
extinction is an important component of PTSD therapy, it follows that HDACi administration in 
PTSD may prove beneficial in diminishing negative learned behavior and enhancing resiliency.   
Our lab recently demonstrated the efficacy of valproic acid (VA) in diminishing ROS and PIC 
escalation in hypertension (Cardinale et al., 2010).  Oxidative stress and inflammation can 
damage neurons and negatively influence synaptic plasticity, so we hypothesized that attenuating 
this effect may diminish PTSD symptoms and improve overall resiliency behavior.  Based on 
this information, this study investigated whether chronic HDACi administration could modulate 
behavior, redox imbalances, inflammation, and neurotransmitters during the progression of 
PTSD, using a predator exposure/psychosocial stress animal model.   
4.2 MATERIALS AND METHODS 
Ethics Statement 
 This study was carried out in accordance with the recommendations of the Institute for 




the auspices of an animal care and use protocol approved by the Louisiana State University 
Institutional Animal Care and Use Committee. 
Animals 
 Naïve adult male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) were used 
in all experiments.  The rats were the same age (12 weeks) and approximately the same weight 
(±15g) upon delivery.  Rats were pair-housed in standard plastic microisolator cages with access 
to food and water ad libitum.  The cages were maintained in ventilated racks and randomly 
assigned to a rack location to ensure groups were evenly distributed.  The vivarium room was 
kept on a 12-hour light/dark cycle (0700-1900), temperature was maintained at 20±1ºC, and 
humidity ranged from 23-42%.  After a 1 week acclimation period, the mean weight of all rats 
was 347.9g ± 4.5.  Two cats, a male and a female (Harlan Laboratories, Indianapolis, IN) were 
used for all predator exposures.  They were housed in an open room (15’ x 15’) in the vivarium 
with access to food, water, and enrichment devices ad libitum.  The cat room was on the same 
light/dark cycle and maintained at similar temperature and humidity. 
Stress Induction 
 The predator exposure/psychosocial stress regimen is designed to induce a PTSD-like 
syndrome as true PTSD is clinically defined as a human disorder.  Following the acclimation 
period, rats were weighed, ear-tagged, tail-marked, and 250-500µL of blood was drawn from the 
tail vein.  The rats were then randomly assigned to the PTSD or control group and returned to the 
vivarium for 24 hours.  The following day, PTSD rats were started on a predator 
exposure/psychosocial stress regimen.  Briefly, PTSD rats were individually isolated in 
cylindrical, Plexiglas containers (IITC Life Science, Inc., Woodland Hills, CA.) and canned cat 




the cats, and the cat food induced movement in the cats.    Rats were then placed in a stainless 
steel cage (76cm x 76cm x 60cm) consisting of a solid metal floor with a hinged, metal rod door, 
with a cat for one hour.  The first cat exposure was conducted during the light cycle (0700-1900).  
Ten days later, a second cat exposure was conducted during the dark cycle (1900-0700).  The 
third exposure was during the light cycle.  In addition, the rats were subjected to psychosocial 
stress by changing their cage cohort daily.  The predator exposure/psychosocial stress regimen 
continued for 40 days, after which certain PTSD and control group rats were administered 
valproic acid (VA) for 30 days.  All groups were then euthanized, perfused with a phosphate 
buffered solution, and the brains were removed.  The hippocampus and PFC were dissected and 
flash-frozen in liquid nitrogen.   
Elevated Plus-Maze 
 Rats were placed in the center of the elevated plus-maze (EPM) (EB-Instruments 
(Bioseb), Tampa Bay, FL) facing an open arm and allowed to roam freely for five minutes.  
Movement was monitored via an overhead camera and captured with a software program 
(BioEPM3C, EB-Instruments, Tampa Bay, FL).  The primary measurements were the total 
number of arm entries and the total time spent in the open vs. closed arms.   
Valproic Acid  
 Rats were pair-housed and administered VA in their water bottles.  Vehicle (water) or 
valproic acid (VA, 0.71% wt/vol, Sigma) dissolved in water were prepared and provided daily 
for 30 days as previously described (Cardinale et al., 2010).   
Electron Paramagnetic Resonance Spectroscopy 
 Superoxide and total ROS (n = 6/group) were measured in whole blood via electron 




total ROS levels were compared between all four groups.  Briefly, blood was incubated at 37°C 
with CMH (200 µM) for 30 min for ROS measurement, PEG-SOD (50 U/µl) for 30 min, then 
CMH (200 µM) for an additional 30 min for O2•− measurement.  Aliquots of incubated probe 
media were then taken in 50-µl disposable glass capillary tubes for determination of O2•− or 
total ROS production.        
Real-Time PCR Analysis  
 Semi-quantitative real-time RT-PCR (n = 6/group) was used to determine the mRNA 
levels of TLR4, NALP3, IL-1β, and IL-18 in the PFC and hippocampus.  The primer sequences 
used for real-time PCR are given (Table 4.1).  Total RNA isolation, cDNA synthesis and RT-
PCR were performed as previously described (Agarwal, Welsch, Keller, & Francis, 2011).   
Table 4.1: Rat primers used for real-time RT-PCR. 
Gene Sense Antisense 
GAPDH agacagccgcatcttcttgt cttgccgtgggtagagtcat 
TLR4 attgttcctttcctgcctga tccagccactgaagttgtga 
NALP3 cagaaggcatgtgagaagca tgggtgtagcgtctgttgag 
IL-1β cagaccactttggcagacttcact ggattcgttggctgttcggtcg 
IL-18 gaccactttggcagacttca tagggtcacagccagtcctc 
TLR4, (Toll-like receptor 4); NALP3, (NACHT, LRR, PYD domains containing protein 3); IL, 
(Interleukin); GAPDH,  (Glyceraldehyde 3-phosphate dehydrogenase). 
Western Blot Analysis 
 Tissue homogenates from the PFC and hippocampus were subjected to Western Blot 
(WB) analysis (n = 6/group) for the determination of protein levels of TLR4, NALP3, IL-1β, IL-
18, TH, TPH, and β-Actin.  The extraction of protein and WB was performed as previously 
described (Agarwal et al., 2011).  Primary antibodies were commercially obtained: IL-1β, IL-18, 
and β-Actin, 1:1000 dilution (SC-7884, SC-7954, and SC-1616R respectively, Santa Cruz 
Biotechnology, Santa Cruz, CA); NALP3, 1:1000 dilution (ORB-101128, Biorbyt, San 




ABCAM, Cambridge, MA); TPH, 1:1000 dilution (AB1541, Millipore, Billerica, MA).  
Secondary antibodies were commercially obtained: anti-rabbit and anti-mouse, 1:5000 dilution 
(SC-2004 and SC-2314 Santa Cruz Biotechnology, Santa Cruz, CA).   
High-Performance Liquid Chromatography (HPLC) 
 Neurotransmitter concentrations were detected using an Eicom HTEC 500 HPLC system.  
The standard solutions of NE (MW 337.3), DA (MW 158.17), 5-hydroxytryptamine (5-HT; MW 
212.68) and isoproterenol (internal standard; MW 247.7) were each 1 ng/µL concentrations.  
Sample preparations were carried out as previously described (Deyama et al., 2008).        
HPLC Detection of Neurotransmitters 
 HPLC system working conditions: isocratic elution; mobile phase (citrate buffer in 
methanol with EDTA and sodium octane sulfonate); Eicompak SC-3ODS (ID 3.0 X 100mm) 
column; flow rate 340 µl/min; graphite working electrode WE-3G (Gasket GS-25), (+750mV 
versus Ag/AgCl electrode); temperature 25°C.   
HPLC Mobile Phase 
 Citric acid monohydrate (8.84 g; mol wt. 210.14), and 3.10g of sodium acetate (mol. wt. 
82.03) in 800 ml of MilliQ Ultrapure fresh water (>18.2MΩ/cm) and 200ml of HPLC grade 
methanol were added.  EDTA (mol. wt. 372.24; 0.005g) and sodium octane sulfonate (0.220 g), 
both from Dojindo Laboratories, Rockville, MD, were added. 
HDAC Activity Analysis 
 Nuclear extracts of PFC and hippocampus tissue were obtained with a Nuclear Extraction 
Kit (K266-100, BioVision, Milpitas, CA).  Nuclear extracts were then analyzed for HDAC 
activity with a colorimetric HDAC Activity Assay Kit (K331-100, BioVision), both according to 




Assessment of NF-kB Activity  
 An ELISA kit (ab133112, Abcam, Cambridge, MA) was used to assess the activity of 
NF-kB in the nuclear extracts of the PFC and hippocampus according to the manufacturer’s 
instructions.   
Statistical Analysis 
 Data are presented as mean ± SEM.  Statistical analysis was conducted by one-way 
ANOVA with a Bonferroni post hoc test for multiple comparisons, unpaired Student’s T-tests for 
two-column analyses, and four-parameter logistic regression for curve fit.  P-values less than 
0.05 were considered significant.  Statistical analyses were performed using Prism (GraphPad 
Software, Inc, La Jolla, CA; version 5.0). 
4.3 RESULTS 
Elevated Plus-Maze Performance 
 Immediately following the stress regimen, the PTSD group spent considerably less time 
in the open vs. closed arms, t(10) = 3.99, p < 0.001.  Overall ambulations, however, were not 
affected, t(10) = 0.88, p > 0.05.  After the 30-day VA treatment, the PTSD+VA group spent 
significantly more time in the open arms vs. the PTSD+Veh  group, F(3, 22) = 41.93, p < 0.01.  
The control group showed no difference between the control+VA and control+Veh groups, F(3, 
22) = 5.17, p > 0.05, (Figure 4.1A).  No differences were found in overall ambulations between 
or within groups, F(3, 22) = 1.52, p > 0.05, (Figure 4.1B).  Repeated measures were also 
conducted to analyze anxiety changes within the same groups over time.  No changes were found  
in the control group between pre-treatment, control+Veh, and control+VA, F(2, 21) = 3.07, p > 
0.05,  (Figure 4.1C).    In the PTSD group, however, significant differences were noted between 





Figure 4.1: The PTSD group spent considerably less time in the open vs. closed arms.  After VA 
treatment, the PTSD+VA group spent significantly more time in the open arms vs. the 
PTSD+Veh group.  The control group showed no difference between the control+VA and 
control+Veh groups (A).  No differences were found in overall ambulations between or within 
groups (B).  Repeated measures found no difference in the control group between pre-treatment, 
control+Veh, and control+VA (C).  In the PTSD group significant differences were noted 
between pre-treatment, PTSD+Veh, and PTSD+VA (D).  All data are presented as mean ± SEM.  
**p < 0.001, ***p < 0.0001 relative to the control group.  ##p < 0.001, ###p < 0.0001 relative to 
the treatment group.  
Oxidative Stress Analysis 
 Analysis of the EPR data revealed superoxide was significantly elevated in whole blood 
in the PTSD group vs. controls, and it diminished with VA, F(3,18) = 2.54, p < 0.05.  No 
difference was noted in the control+VA vs. the control+Veh groups, t(8) = 0.07, p > 0.05  




was also decreased with VA, F(3,18) = 3.13, p < 0.05.  No difference was noted in the 
control+VA vs. the control+Veh groups, t(8) = 0.64, p >0.05 (Figure 4.2B).    
Brain Inflammatory Markers  
 The PTSD group demonstrated elevated mRNA levels of TLR4, F(3,12) = 6.37 and 7.14, 
p < 0.05 (Figures 4.3A&B), NALP3, F(3,12) = 5.69 and 17.10, p < 0.05 (Figures 4.3C&D), IL-
1β, F(3,12) = 6.08 and 2.85, p < 0.05 and p > 0.05 (Figures 4.3E&F) and IL-18, F(3,12) = 44.84 
and 5.45, p < 0.05 (Figures 4.3G&H).  Valproic acid administration normalized the upregulated 
mRNA to levels similar to the untreated controls.  In the PFC (Figure 4.3I) and hippocampus 
(Figure 4.3J), both regions also demonstrated elevated protein levels of TLR4, F(3,4) = 30.52 
and 454.70, p < 0.05, NALP3, F(3,4) = 9.42 and 27.67, p < 0.05, IL-1β, F(3,4) = 12.03 and 
12.83, p < 0.05, and IL-18, F(3,4) = 130.0 and 50.18, p < 0.05.  Valproic acid administration also 
attenuated the upregulated protein to levels similar to the untreated controls.      
 
Figure 4.2: Superoxide (A) and total ROS (B) were significantly elevated in the circulating blood 
in the PTSD group.  The elevation was normalized to control group levels with VA.  All data are 
presented as mean ± SEM.  *p < 0.05 relative to the control group.  #p < 0.05, ##p < 0.001 






Figure 4.3: In the PFC, mRNA levels of TLR4, NALP3, IL-1β, and IL-18 were elevated in the 
untreated PTSD vs. control group, which was normalized with VA (A, C, E, G).  In the 
hippocampus, mRNA levels of TLR4, NALP3, and IL-18 were elevated in the untreated PTSD 
vs. control group, which was normalized with VA (B, D, H).  IL-1β was elevated vs. the 
control+Veh group and PTSD+VA group, but did not reach significance (F).  All data presented 
as mean ± SEM.  *p < 0.05, ***p < 0.0001 relative to the control group.  #p < 0.05, ###p < 
0.0001 relative to the treatment group. 
HDAC Activity 
 Analysis of HDAC activity in the PFC revealed increased HDAC in the untreated PTSD 
group vs. controls, which was subsequently attenuated with VA (Figure 4.4A), F(3,17) = 3.282, 




group (did not reach significance), but it was significantly downregulated in the PTSD+VA 
group (Figure 4.4B), F(3,17) = 2.006, p < 0.05.   
NF-κB Transcription 
 The transcription factor NF-κB was significantly elevated in the PFC in the untreated 
PTSD group vs. controls, which was normalized with VA (Figure 4.4C), F(3,17) = 13.86, p < 
0.0001.  In the hippocampus, NF-κB was also upregulated in the untreated PTSD group vs. 
controls, which was subsequently downregulated with VA (Figure 4.4D), F(3,17) = 16.66, p < 
0.0001.  
Neurotransmitter Modulation  
 In the PFC, the catecholamines NE (Figure 4.5A) and DA (Figure 4.5C) were 
significantly higher in the PTSD group vs. controls, F(3,17) = 8.66 and F(3,17) = 36.32, p < 
0.05, respectively.  Conversely, 5-HT (Figure 4.5E) was significantly lower in the PTSD group 
vs. controls, F(3,17) = 7.41, p < 0.05.  Valproic acid administration lowered catecholamine levels 
and increased 5-HT to levels similar to the untreated controls.  In the hippocampus, NE (Figure 
4.5B) was significantly higher in the PTSD group vs. controls, F(3,17) = 58.57, but no 
significant difference was found in DA levels, F(3,17) = 1.56, p > 0.05.  The level of 5-HT 
(Figure 4.5E) was lower in the PTSD group vs. controls, F(3,17) = 30.65, p < 0.05.  Valproic  
acid administration lowered NE levels and increased 5-HT to levels similar to the untreated 
controls. 
4.4 DISCUSSION  
 The present study sought to analyze the effects of HDACi administration on the behavior 
and physiology associated with PTSD by employing a predator exposure/psychosocial stress 





Figure 4.4: In the PFC, HDAC was increased in the untreated PTSD vs. control group, which 
was subsequently attenuated with VA (A).  HDAC activity in the hippocampus was elevated in 
the untreated PTSD vs. control group (did not reach significance), but it was significantly 
downregulated in the PTSD+VA group (B).  NF-κB was also elevated in the PFC (C) and 
hippocampus (D) in the untreated PTSD vs. untreated control group, which was normalized with 
VA.  All data presented as mean ± SEM.  *p < 0.05, ***p < 0.0001 relative to the control group.  
#p < 0.05, ###p < 0.0001 relative to the treatment group.  
particular model that seems to meet face, predictive, and construct validity is the predator 
exposure/psychosocial stress regimen (Daskalakis, Yehuda, & Diamond, 2013).  The model by 
Zoladz et al. has been shown to cause heightened anxiety, exaggerated startle response, impaired 





Figure 4.5: In the PFC, the catecholamines NE (A) and DA (C) were significantly higher in the 
PTSD group vs. controls, F(3,17) = 8.66 and F(3,17) = 36.32, p < 0.05, respectively.  
Conversely, the monoamine 5-HT (E) was significantly lower in the PTSD group vs. controls, 
F(3,17) = 7.41, p < 0.05.  VA administration lowered catecholamine levels and increased 5-HT 
to levels similar as the untreated controls.  In the hippocampus, NE (B) was significantly higher 
in the PTSD group vs. controls, F(3,17) = 58.57, but no significant difference was found in DA 
(D) levels, F(3,17) = 1.56, p > 0.05.  The level of 5-HT (F) was lower in the PTSD group vs. 
controls, F(3,17) = 30.65, p < 0.05.  Valproic acid administration lowered NE levels and 
increased 5-HT to levels similar as the untreated controls.  **p < 0.001, ***p < 0.0001 relative to 
the control group.  ##p < 0.001, ###p < 0.0001 relative to the treatment group. 
which are common symptoms reported in humans with PTSD (Brewin, Andrews, & Valentine, 
2000; Nemeroff et al., 2006).  In addition, our lab recently demonstrated that the predator 
exposure model produced neurotransmitter modulation and altered catecholamine and 5-HT rate-




neurologic disorders and show efficacy as anti-inflammatory agents, their utility in PTSD 
treatment has been largely unexplored.  We have successfully obtained data with this model 
indicating HDACi (VA) may be a promising pharmacologic therapy for PTSD patients.  Three 
novel and important findings emerged from this study.  First, increased oxidative stress and 
inflammation in the brain and blood in response to psychological stress are attenuated with VA.  
Second, the aberrant neurotransmitter profile of increased catecholamines and decreased 5-HT 
was normalized with VA.  Lastly, VA seems to enhance resiliency behavior as indicated by 
reduced anxiety levels in the PTSD+VA group.    
 Histone deacetylases (HDAC), along with histone acetyltransferases (HAT), modulate 
gene expression by decreasing or increasing gene availability, respectively.  HDACs and HATs 
act in concert with one another, maintaining homeostasis during normal cellular functions (de 
Ruijter et al., 2003).  During abnormal states, however, this imbalance is tilted in favor of HDAC 
activity, resulting in increased oxidative stress and inflammation (Aung et al., 2006; Halili, 
Andrews, Sweet, & Fairlie, 2009; H. J. Kim et al., 2007).  It is an oversimplification to state that 
acetylation increases and deacetylation decreases gene expression, as research has shown that 
non-histone proteins can be reversibly acetylated, which drastically affects their function (M. S. 
Kim et al., 2001).  Current research has demonstrated that elevation of PIC expression can 
increase HDAC activity, which is directly proportional to heighted NF-κB transcription and 
further production of PICs (Keslacy et al., 2007).  As a result, HDAC inhibition may be relevant 
to treatment of neuroinflammatory disorders (Kazantsev & Thompson, 2008).  Our findings that 
a PTSD-like syndrome increases NF-κB expression and HDAC activity in the  stressed animals 




inflammatory mediators in the PTSD+VA group confirms previous findings that HDACi have 
anti-inflammatory properties.     
 The roles of oxidative stress and inflammation in pathological conditions such as 
cardiovascular disease, diabetes mellitus, metabolic syndrome, and neurological diseases are 
well established (Agarwal et al., 2011; Alexopoulos et al., 2012; Elks & Francis, 2010; Pall & 
Satterlee, 2001).  We recently demonstrated increased oxidative stress and inflammation in the 
brain and systemic circulation of rats subjected to the predator exposure model (Wilson et al., 
2013).  Reactive oxygen and nitrogen radicals have unpaired electrons that can cause damage by 
oxidizing proteins, lipids, nucleic acids, and other cellular components.  The damage caused by 
ROS can activate transcription factors such as NF-κB, leading to increased production of 
cytokines and chronic inflammation (Reuter, Gupta, Chaturvedi, & Aggarwal, 2010).  
Immunomodulating cytokines function to transmit information concerning inflammatory 
responses to the CNS (Chrousos, 2000a; Dunn, 2000; McCann et al., 2000; Turnbull, Lee, & 
Rivier, 1998).  The CNS then participates in negative feedback regulation of the peripheral 
immune response by releasing pituitary hormones and norepinephrine (NE) which increase 
sympathetic drive.  In chronic stress-related conditions such as PTSD, however, a sustained 
sympathoexcitatory state can alter the Th1/Th2 cell balance and actually increase PIC production 
(Chrousos, 2000b).     
 A primary initiator of the inflammatory response is the inflammasome, a multi-protein 
complex that upregulates PICs.  In our previous work, we demonstrated that the NALP3 
inflammasome was upregulated in the predator exposure/psychosocial stress PTSD model 
(Wilson et al., 2013).  NALP3, possibly in a two-stage process with TLR4, utilizes caspase-1 to 




inflammatory components.  A few of these components have been implicated in PTSD 
pathophysiology.  Studies show that PTSD was exacerbated by increased levels of NO and other 
ROS, causing cellular damage in the hippocampus (Oosthuizen et al., 2005).  Other research 
discovered DNA breakage in the hippocampus of rats subjected to stress (Diehl et al., 2012).  
Inflammasomes are primarily found in resident macrophages and granulocytes, but they are also 
key inflammatory mediators in non-myeloid cells (Yazdi, Drexler, & Tschopp, 2010), which 
may explain the increase in PICs in the blood and periphery during PTSD progression.      
One of the diagnostic criteria for PTSD is hyperarousal, which includes an exaggerated startle 
response and heightened anxiety (American, 2013).  Previous research with the predator 
exposure model also demonstrated memory-related impairments of the hippocampus during 
anxiety testing (Diamond, Park, Heman, & Rose, 1999).  To measure anxiety levels, we used the 
elevated plus-maze (EPM).  Rodents have a natural tendency to explore novel environments, but 
open areas or alleys invoke a greater fear and avoidance response (Montgomery, 1955).  The 
EPM is widely used as a measure to test anxiety and has been extensively validated for use in 
rats (Korte & De Boer, 2003; Pellow, Chopin, File, & Briley, 1985).  Entry into the open areas is 
associated with increased freezing behavior as well as increased plasma corticosterone levels, 
indicating heightened anxiety (Pellow et al., 1985).  Anxiogenic compounds or procedures can 
increase avoidance of the fear-provoking open arms, whereas anxiolytic compounds or 
procedures can increase open arm exploration (Pellow et al., 1985).  The primary criteria 
correlated with anxiety levels are total arm entries and the percent time spent in the open vs. 
closed arms.  We found that VA had an anxiolytic effect, as rats in the PTSD+VA group 




 The modulation of various neurotransmitters observed with the predator 
exposure/psychosocial stress model is in concert with many of the neurotransmitter changes seen 
in human PTSD patients (Arora, Fichtner, O'Connor, & Crayton, 1993; Geracioti et al., 2001; 
Geracioti et al., 2013; Yehuda, Southwick, Giller, Ma, & Mason, 1992).  Previous research has 
shown that stress blocks hippocampal long-term potentiation (LTP) and impairs its function 
(Diamond, Campbell, Park, Halonen, & Zoladz, 2007).  The hippocampus is the primary region 
for spatial and long-term memory storage and expresses all of the 5-HT receptor families, which 
reflects the overall serotonergic functions relating to cognition and mood in this region 
(Berumen, Rodriguez, Miledi, & Garcia-Alcocer, 2012).  In addition, the hippocampus has the 
highest density of glucocorticoid receptors compared to other brain regions (McEwen, Weiss, & 
Schwartz, 1969).  During stress, glucocorticoid production can reduce the excitability of 
hippocampal neurons, and 5-HT may have a protective effect against such damage by activating 
5-HT1A receptors (Joca, Ferreira, & Guimaraes, 2007).  Persistent activation of the HPA axis 
and excessive production of glucocorticoids, however, may directly reduce hippocampal 5-HT 
levels and adversely affect normal serotonergic transmission, thus contributing to heightened 
fear, depressed mood, and reduced resilience.  The hippocampus also contains multiple NE 
receptors which, when activated during stress, may contribute to the reinforcement of long-term 
memories (Jurgens et al., 2005).  In a study by Geracioti et al. involving male combat veterans 
with PTSD, CSF concentrations of NE were significantly higher vs. controls (Geracioti et al., 
2001).  This finding could possibly explain why memories formed during extremely stressful 
events persist over time.  Other evidence of catecholamine dysregulation in PTSD includes 
elevated urine catecholamine excretion, exaggerated biochemical responses to yohimbe, and 




also noted with previous experiments utilizing the predator exposure/psychosocial stress animal 
model and treatments with selective serotonin reuptake enhancers (SSRE), α2 agonists, and 
tricyclic antidepressants (Zoladz, Fleshner, & Diamond, 2013).  Although we found no 
significant difference in DA levels in the hippocampus, we noted a reduction in homovanillic 
acid (HVA) levels (not shown), which was consistent with current human PTSD research 
(Geracioti et al., 2013).  HVA is a downstream product of DA metabolism, and traumatic stress 
may impede CNS release of DA from the substantia nigra and ventral tegmental area (VTA) 
(Cabib & Puglisi-Allegra, 2012), the primary CNS regions of dopaminergic neurons, thus 
reducing metabolite concentration.     
 The PFC, responsible for executive functions such as consequences, drive, and social 
“control”, is highly innervated by serotonergic neurons from the raphe nuclei and also expresses 
an abundance of 5-HT receptors.  The 5-HT1A and 5-HT2A receptors are a key modulator of the 
PFC-amygdala corticolimbic circuit involved in threat and emotional responses (Fisher et al., 
2011).  PTSD-related aberrancies in this serotonergic system may cause inappropriate or 
incomplete extinction of conditioned fear.  The PFC also contains NE receptors and receives 
input from NE neurons from the locus coeruleus, which are activated during the stress response 
(Finlay, Zigmond, & Abercrombie, 1995).  Pathogical or stress-related elevations of NE in the 
PFC, however, may inhibit working memory and performance (Zhang, Cordeiro Matos, Jego, 
Adamantidis, & Seguela, 2013).  Current neuroimaging research indicates the PFC is 
hyporesponsive during symptomatic PTSD states and responsiveness is inversely proportional to 
symptom severity (Shin, Rauch, & Pitman, 2006).  In contrast to unchanged DA levels in the 
hippocampus, DA levels were significantly increased in the PFC, which was similar to the CSF 




Yehuda et al., 1992).  In a similar manner to NE, stress-related elevations of DA may also impair 
working memory and performance.  The PFC is densely innervated by dopaminergic neurons 
from the VTA, and dopamine release can be achieved via VTA or local stimulation.  A recent 
study by Butts et al. demonstrated that stress-induced glucocorticoid stimulation of DA neurons 
caused a local release of DA in the PFC (Butts, Weinberg, Young, & Phillips, 2011).  These data 
support the theory that overstimulation of the HPA axis and the resulting elevation in 
glucocorticoid activity can directly modulate DA and other neurotransmitters.  Taken together, 
our findings that VA was able to increase 5-HT and decrease catecholamine levels in the brain, 
apparently by modulating levels of the rate-limiting enzymes for the respective 
neurotransmitters, represents a completely novel finding in an animal model of PTSD and 
demonstrates a valid justification for VA as an alternative to currently accepted 
pharmacotherapy.   
4.5 CONCLUSIONS 
 This study was conducted to test alternative pharmacologic therapies for PTSD, as the 
currently approved selective-serotonin reuptake inhibitors (SSRI) have proven nominally 
effective (Tawa & Murphy, 2013).  Based on their mechanism of action, SSRIs should increase 
5-HT levels and attenuate many of the detrimental effects of lowered 5-HT.  This concept has 
proven effective in the treatment of depression (Doogan & Caillard, 1992; Miller et al., 1998).  
In PTSD, however, SSRI efficacy can be classified as questionable at best.  In a study by 
Davidson et al., they demonstrated decreased severity of symptoms and an overall increase in 
functioning in the PTSD patients vs. controls (Davidson, Rothbaum, van der Kolk, Sikes, & 
Farfel, 2001).  This study, however, had uneven gender,  racial, and traumatic event distribution.  




36% increase in the placebo group.  Taken together, the numbers indicate a significant portion of 
the noted improvement may be due to a placebo effect.  The study did not perform physiological 
testing and therefore could not anticipate modulation of other neurotransmitters in response to 
serotonin reuptake.  We have achieved such data and have successfully demonstrated that VA 
produces both physiological and behavioral changes in animals with a PTSD-like syndrome.   
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DIFFERENTIAL EFFECTS OF SERTRALINE IN A PREDATOR EXPOSURE 
ANIMAL MODEL OF POST-TRAUMATIC STRESS DISORDER 
 
5.1 INTRODUCTION 
Post-traumatic stress disorder (PTSD), an anxiety disorder recently reclassified as a 
trauma- and stressor-related disorder, can develop in response to real or perceived life-
threatening situations.  According to the Diagnostic and Statistical Manual of Mental Disorders 5 
(DSM-5), a diagnosis of PTSD necessitates exposure to a traumatic event, intrusive 
recollections, avoidance of associated stimuli, negative cognitions/mood, hyperarousal, and a 
significant social impairment.  All of these symptoms must persist for at least 30 days and not be 
due to illness, medication, or substance abuse (American Psychiatric Association, 2013).  To 
date, no definitive diagnostic biomarkers have been identified for PTSD.  Recent research, 
however, points toward physiological abnormalities in the hypothalamic-pituitary-adrenal (HPA) 
axis, sympathoadrenal medullary system, immune system, and neurotransmitters that may be 
implicated in the disorder (Liberzon, Abelson, Flagel, Raz, & Young, 1999; Oosthuizen, 
Wegener, & Harvey, 2005; Sondergaard, Hansson, & Theorell, 2004; Wilson, Ebenezer, 
McLaughlin, & Francis, 2014; Wilson et al., 2013).  Although neurotransmitters are modulated 
in PTSD development, it remains unclear whether 5-HT is the only neurotransmitter affected by 
selective-serotonin reuptake inhibitors (SSRI).  Changes in levels of other neurotransmitters 
might explain why SSRIs have met with such mixed results in PTSD therapy (Davidson, 
Rothbaum, van der Kolk, Sikes, & Farfel, 2001; Watts et al., 2013).  To evaluate the effects of 
sertraline on neurotransmitter modulation, we employed a well-documented predator 
exposure/psychosocial stress animal model of PTSD demonstrating three hallmark features of 




(Zoladz, Conrad, Fleshner, & Diamond, 2008; Zoladz, Fleshner, & Diamond, 2012).  This model 
also possesses both predictive and construct validity, making it sensitive to clinically effective 
pharmacologic agents while displaying similarities to human PTSD (Bourin, Petit-Demouliere, 
Dhonnchadha, & Hascoet, 2007).       
Serotonin (5-HT) is a neurotransmitter responsible for many functions in the CNS and 
periphery.  Serotonergic cell bodies originate primarily in the raphe nuclei, but every area of the 
central nervous system (CNS) receives 5-HT innervation (McGeer, 1987).  It influences 
aggression, arousal, sleep, anxiety, appetite, fear, learning, and other processes (Dubovsky, 
1994).  5-HT is also the principle regulator of mood.  A study by Peirson et al. (Peirson & 
Heuchert, 2000) found lower platelet 5-HT2 receptor function was associated with depressed 
mood, while Williams et al. (Williams et al., 2006) demonstrated higher blood 5-HT levels were 
correlated with better mood.  An increased mood and overall sense of well-being has been 
shown, in both psychiatric and physical disorders, as protective and positively correlated with 
resiliency behavior (Delamothe, 2005).  Research has also demonstrated that 5-HT-uptake sites 
in platelets were lower in PTSD patients vs. controls (Arora, Fichtner, O'Connor, & Crayton, 
1993).  Lower 5-HT has also been implicated in diminished physical health.  Muldoon et al. 
showed that a low prolactin response to fenfluramine, a drug that increases 5-HT levels, was 
associated with metabolic syndrome (Muldoon et al., 2004).  Based on 5-HT’s action, it is 
reasonable to surmise SSRIs should be effective in PTSD.  The SSRIs sertraline and paroxetine 
are the only Food and Drug Administration (FDA) approved drugs for PTSD, but the modulation 
of other neurotransmitters in response to 5-HT reuptake has yet to be clearly delineated.   
Norepinephrine (NE) is a neurotransmitter involved in the regulation of psychiatric and 




modulates multiple functions such as neuroplasticity, attention and memory, emotions, and 
psychological stress (Benarroch, 2009).  The LC also has projections to the spinal cord where 
NE is released from postganglionic neurons in the sympathetic nervous system to initiate the 
‘fight-or-flight’ response.  In addition, chromaffin cells in the adrenal medulla release NE and 
epinephrine into the bloodstream, increasing heart rate and blood flow to skeletal muscles and 
triggering the release of glucose.  Persistent noradrenergic activity, however, has been linked 
with negative outcomes in patients with congestive heart failure (CHF) (Francis et al., 1993) and 
diabetes (Ganguly, Dhalla, Innes, Beamish, & Dhalla, 1986).  Studies have also shown that 
individuals with PTSD have elevated cerebrospinal fluid (CSF) levels of NE (Geracioti et al., 
2001) and noradrenergic hyperresponsiveness to various stimuli (Liberzon et al., 1999).  
Moreover, dysregulation of noradrenergic neurons has been associated with hyperarousal and 
intrusive recollections attributable to PTSD (Southwick et al., 1999).  A study by Bracha et al. 
noted irregularities in the number of cells of the LC in postmortem examinations of combat 
veterans diagnosed with PTSD (Bracha, 2005).  Thus, neurotransmitter modulation resulting in 
elevated NE levels might increase sympathetic drive and elevate anxiety.  
Since the late 1980s, SSRIs have proven effective in the treatment of depression (Doogan 
& Caillard, 1992; I. W. Miller et al., 1998).  In PTSD, however, SSRI efficacy can be classified 
as inconsistent at best (Friedman, Marmar, Baker, Sikes, & Farfel, 2007).  A study by Davidson 
et al. which was a part of the FDA approval process for sertraline use in PTSD, demonstrated 
decreased severity of symptoms and an overall increase in functioning in the PTSD patients vs. 
controls (Davidson et al., 2001).  The results were achieved with multiple investigator- and self-
rated assessments.  This study, however, had uneven gender distribution (84% female), racial 




efficacy of sertraline in PTSD, therefore, may be variable due to gender, demographics, and/or 
type of incident.  The data showed a 45% increase in symptom improvement in the treatment 
group, but also a 36% increase in symptom improvement in the placebo group.  Taken together, 
these numbers indicate that the majority of the noted improvement may be due to a placebo 
effect.  In addition, there were no physiological measures conducted to analyze actual 
neurotransmitter modulation during treatment.  This information could be critical in determining 
the true efficacy of SSRIs, as neurotransmitter changes are not mutually exclusive events.  With 
this in mind, this study sought to analyze the modulation of neurotransmitters and inflammatory 
components in the hippocampus, prefrontal cortex (PFC), CSF, and plasma after a 7-day 
sertraline treatment regimen.                                                                       
5.2 MATERIALS AND METHODS 
Ethics Statement 
This study was carried out in accordance with the recommendations of the Institute for 
Laboratory Animal Research’s 2011 Guide for the Care and Use of Laboratory Animals, under 
the auspices of an animal care and use protocol approved by the Louisiana State University 
Institutional Animal Care and Use Committee. 
Animals 
Naïve adult male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) were used 
in all experiments.  The rats were the same age (12 weeks) and approximately the same weight 
(±15g) upon delivery.  Rats were pair-housed in standard plastic microisolator cages with access 
to food and water ad libitum.  The cages were maintained in ventilated racks and randomly 
assigned to a rack location to ensure groups were evenly distributed.  The vivarium room was 




humidity ranged from 23-42%.  After a 1-week acclimation period, the mean weight of all rats 
was 308.5g ± 2.5.  Two cats, a male and a female (Harlan Laboratories, Indianapolis, IN) were 
used for all predator exposures.  They were housed in an open room (15’ x 15’) in the vivarium 
with access to food, water, and enrichment devices ad libitum.  The cat room was on the same 
light/dark cycle and maintained at a similar temperature and humidity. 
Stress Induction 
The predator exposure/psychosocial stress regimen is designed to induce a PTSD-like 
syndrome as true PTSD is clinically defined as a human disorder.  Following the acclimation 
period, rats were weighed, ear-tagged, tail-marked, and 250-500µL of blood was drawn from the 
tail vein.  The rats were then randomly assigned to the PTSD or control group and returned to the 
vivarium for 24 hours.  The following day, PTSD rats were started on a predator 
exposure/psychosocial stress regimen.  Briefly, PTSD rats were individually isolated in 
cylindrical, Plexiglas containers (IITC Life Science, Inc., Woodland Hills, CA.) and canned cat 
food was smeared on the outside of the cylinders.  The cylinders prevented direct contact with 
the cats, and the cat food induced movement in the cats.    Rats were then placed in a stainless 
steel cage (76cm x 76cm x 60cm) consisting of a solid metal floor with a hinged, metal rod door, 
with a cat for one hour.  The first cat exposure was conducted during the light cycle (0700-1900).  
Ten days later, a second cat exposure was conducted during the dark cycle (1900-0700).  In 
addition, the rats were subjected to psychosocial stress by changing their cage cohort daily.  The 
predator exposure/psychosocial stress regimen continued for 31 days, after which certain PTSD 
and control group rats were administered sertraline intraperitoneally (i.p.) for 7 days.  All groups 




exsanguination via perfusion was conducted with a phosphate buffered solution, and the brains 
were removed.  The hippocampus and PFC were dissected and flash-frozen in liquid nitrogen.  
Elevated Plus-Maze (EPM) 
Rats were randomly selected for either the control or the PTSD group and were 
administered a baseline EPM prior to the predator exposure.  The EPM was also administered 
after the 31-day stress regimen and again after the 7-day sertraline treatment.  Rats were placed 
in the center of the elevated plus-maze (EPM) (EB-Instruments (Bioseb), Tampa Bay, FL) facing 
an open arm and allowed to roam freely for five minutes.  Movement was monitored via an 
overhead camera and captured with a software program (BioEPM3C, EB-Instruments, Tampa 
Bay, FL).  The primary measurements were the total number of arm entries and the total time 
spent in the open vs. closed arms.   
Sertraline  
Rats were pair-housed and treatment group animals were injected i.p. with sertraline HCl 
dissolved in 50% dimethyl sulfoxide (DMSO) and dH2O at 10mg/kg for 7 consecutive days 
(Maj & Rogoz, 1999).  Control rats were injected i.p. with vehicle.  
Real-Time PCR Analysis  
Semi-quantitative real-time RT-PCR (n = 6/group) was used to determine the mRNA 
levels of interleukin-1β (IL-1β), interleukin-4 (IL-4), interleukin-10 (IL-10), and Toll-like 
receptor-4 (TLR4) in the PFC and hippocampus.  Total RNA isolation, cDNA synthesis and RT-
PCR were performed as previously described (Agarwal, Welsch, Keller, & Francis, 2011).  Gene 
expression was measured by the ΔΔCT method and was normalized to GAPDH mRNA levels.  




GAPDH,  (Glyceraldehyde 3-phosphate dehydrogenase); IL, (Interleukin); TLR4, (Toll-like 
receptor 4). 
Western Blot Analysis 
Tissue homogenates from the PFC and hippocampus were subjected to Western Blot 
(WB) analysis (n = 6/group) for the determination of protein levels of IL-1β, IL-4, IL-10, TLR4, 
and β-Actin.  The extraction of protein and WB was performed as previously described (Agarwal 
et al., 2011).  Primary antibodies were commercially obtained: IL-1β, and β-Actin, 1:1000 
dilution (SC-7884 and SC-1616R respectively, Santa Cruz Biotechnology, Santa Cruz, CA), 
TLR4, IL-4, and IL-10, 1:1000 dilution (ab13556, ab9811, and ab9969 respectively, Abcam, 
Cambridge, MA).  Secondary antibodies were commercially obtained: anti-rabbit, 1:5000 
dilution (SC-2004, Santa Cruz Biotechnology, Santa Cruz, CA.). 
High-Performance Liquid Chromatography (HPLC) 
Neurotransmitter concentrations were detected using an Eicom HTEC 500 HPLC system.  
The standard solutions of NE (MW 337.3), 5-HT (MW 212.68) and isoproterenol (internal 
standard; MW 247.7) were each 1 ng/µL concentrations.  Sample preparations were carried out 
as previously described (Deyama et al., 2008; Wilson et al., 2013, 2014).        
HPLC Detection of Neurotransmitters 
HPLC system working conditions: isocratic elution; mobile phase (citrate buffer in 
methanol with EDTA and sodium octane sulfonate); Eicompak SC-3ODS (ID 3.0 X 100mm) 
column; flow rate 340 µl/min; graphite working electrode WE-3G (Gasket GS-25), (+750mV 






HPLC Mobile Phase 
Citric acid monohydrate (8.84 g; mol wt. 210.14), and 3.10g of sodium acetate (mol. wt. 
82.03) in 800 ml of MilliQ Ultrapure fresh water (>18.2MΩ/cm) and 200ml of HPLC grade 
methanol were added.  EDTA (mol. wt. 372.24; 0.005g) and sodium octane sulfonate (0.220 g), 
both from Dojindo Laboratories, Rockville, MD, were added. 
ELISA Analysis  
An ELISA kit was used to measure NE (MBS881383, MyBioSource, San Diego, CA.) 
levels in the CSF and plasma according to manufacturer’s instructions.  
Statistical Analysis 
Data are presented as mean ± SEM.  Statistical analysis was conducted by one-way 
ANOVA with a Bonferroni post hoc test for multiple comparisons, unpaired Student’s T-tests for 
two-column analyses, and four-parameter logistic regression for curve fit.  P-values less than 
0.05 were considered significant.  Statistical analyses were performed using Prism (GraphPad 
Software, Inc, La Jolla, CA; version 5.0). 
5.3 RESULTS 
Elevated Plus-Maze Performance 
Prior to the start of the stress regimen, there were no differences noted in baseline open 
arm exploration (Figure 5.1A) or total arm entries (Figure 5.1B).  After the 31-day stress 
regimen, the PTSD group spent considerably less time in the open vs. closed arms as compared 
to the control group, t(22) = 5.10, p < 0.05, and as compared to baseline, t(22) = 3.86, p < 0.05 
(Figure 5.1A).  Overall ambulations, however, were not affected, F(3,44) = 0.974, p > 0.05 
(Figure 5.1B).  After the 7-day sertraline treatment, the PTSD+Sert group displayed no increased 




t(10) = 4.59, p < 0.05.  The control group also showed no difference between the control+Sert 
and control+Veh groups, t(10) = 0.43, p > 0.05, (Figure 5.2A).  No differences were found in 
overall ambulations between or within groups after the sertraline treatment, F(3, 20) = 0.55, p > 
0.05, (Figure 5.2B).  
CSF and Plasma NE Analysis 
In the CSF, NE was elevated in the PTSD+Veh vs. the control+Veh group, t(8) = 4.22, p 
< 0.05.  Sertraline raised NE levels in the control+Sert vs. the control+Veh group, t(8) = 4.96, p 
< 0.05, and NE was further elevated in the PTSD+Sert vs. the PTSD+Veh group, t(8) = 3.72, p < 
0.05 (Figure 5.3A).  In the plasma, NE was higher in the treatment groups, but it did not reach 
significance in any comparisons (Figure 5.3B).     
Inflammatory Markers 
In the PFC and hippocampus, the PTSD group demonstrated elevated mRNA levels of 
IL-1β, F(3,18) = 3.56, p < 0.05 and F(3,20) = 3.53, p < 0.05  (Figures 5.4A&B) and TLR4, 
F(3,20) = 4.11, p < 0.05 and F(3,20) = 1.44, p > 0.05 (Figures 5.4C&D).  Conversely, there were 
diminished levels of IL-4, F(3,20) = 0.99, p > 0.05 and F(3,20) = 6.65,p < 0.05 (Figures 5.4E&F) 
and IL-10, F(3,20) = 9.57, p < 0.05 and F(3,20) = 7.34, p < 0.05 (Figures 5.4G&H)  in the same 
regions.  Sertraline administration normalized the elevated PIC mRNA and up-regulated anti-
inflammatory cytokine (AIC) to levels similar to or higher than the control+Veh group.  The 
PTSD group also displayed elevated protein levels in the PFC and hippocampus of IL-1β, F(3,4) 
= 53.04, p < 0.05 and F(3,4) = 22.15, p < 0.05 (Figures 5.5A&B) and TLR4, F(3,4) = 25.78, p < 
0.05 and F(3,4) = 43.14, p < 0.05 (Figures 5.5C&D).  The levels of AIC protein were lower for 




13.16, p < 0.05 and F(3,4) = 134.10, p < 0.05 (Figures 5.5G&H).  Sertraline administration also 
normalized the aberrant protein to levels similar to the control+Veh group.   
 
Figure 5.1: The PTSD group spent considerably less time in the open vs. closed arms compared 
to the control group and to baseline (A).  There were no differences noted in overall ambulations 
between or within groups (B).   All data are presented as mean ± SEM.  *p < 0.05 relative to the 
control group.  #p < 0.05 relative to within group measurements (baseline). 
 
Neurotransmitter Modulation 
To investigate the influence of sertraline on neurotransmitter modulation, we examined 
endogenous levels of biogenic amines in the hippocampus and PFC of control and PTSD animals 
using HPLC.  In the PFC, the level of the tryptamine 5-HT (Figure 5.6A) was significantly lower 
in the PTSD+Veh vs. the control+Veh group, t(10) = 6.64, p < 0.05.  Conversely, the level of the 
catecholamine NE (Figure 5.6B) was significantly higher in the PTSD+Veh group, t(10) = 8.04, 
p < 0.05.  Sertraline expectedly raised 5-HT levels in the PTSD+Sert and control+Sert groups to 





Figure 5.2: After sertraline treatment, the PTSD+Sert group demonstrated no measureable 
improvement vs. the control+Sert group, and the PTSD+Veh group displayed persistent anxiety 
vs. the control+Veh group (A).  There were no differences in overall ambulations in any of the 
four groups after the treatment period (B).  All data are presented as mean ± SEM.  *p < 0.05 
between the treatment groups.  #p < 0.05 between the vehicle groups. 
elevated NE in the PTSD+Sert and control+Sert groups to levels higher than the control+Veh 
group F(3,20) = 26.59, p < 0.05 (Figure 5.6B).  In the hippocampus, 5-HT (Figure 5.6C) was 
significantly lower in the PTSD+Veh vs. the control+Veh group, t(10) = 6.03, p < 0.05, while 
NE (Figure 5.6D) was higher, t(10) = 8.94, p < 0.05.  Similar to results in the PFC, sertraline 
normalized 5-HT to pre-stress levels, F(3,20) = 18.35, p < 0.05 (Figure 5.6C), but it doubled NE 
in the control+Sert group and more than tripled NE in the PTSD+Sert group compared to the 






Figure 5.3: In the CSF, NE was elevated in the PTSD+Veh vs. the control+Veh group and in the 
control+Sert vs. the control+Veh group.  NE was further elevated in the PTSD+Sert vs. the 
PTSD+Veh group (A).  In the plasma, NE was higher in the treatment groups, but it did not 
reach significance in any comparisons (B).  All data are presented as mean ± SEM.  *p < 0.05 
between the PTSD groups.  @p < 0.05 between the control groups.  #p < 0.05 between the 
vehicle groups. 
5.4 DISCUSSION  
The present study sought to analyze neurotransmitter modulation and pro- and anti-
inflammatory cytokines in the PFC, hippocampus, CSF, and plasma of rats subjected to a PTSD 
model and subsequently treated with sertraline.  A myriad of animal models designed to create 
PTSD-like effects are reported, but the model by Zoladz et al. has been shown to cause common 
symptoms reported in humans with PTSD (Brewin, Andrews, & Valentine, 2000; Nemeroff et 
al., 2006) such as heightened anxiety, exaggerated startle response, impaired cognition, and 







Figure 5.4: In the PFC and hippocampus, the PTSD group demonstrated elevated mRNA levels 
of IL-1β (A&B) and TLR4 (C&D).  Conversely, there were diminished levels of IL-4 (E&F) and 
IL-10 (G&H) in the same regions.  Sertraline administration normalized the elevated PIC mRNA 
and up-regulated anti-inflammatory cytokine (AIC) to levels similar to or higher than the 
control+Veh group.  All data are presented as mean ± SEM.  *p < 0.05 between the PTSD 









Figure 5.5: The PFC and hippocampus demonstrated elevated protein levels of IL-1β (A&B) and 
TLR4 (C&D) in the PTSD group.  Conversely, the levels of AIC protein in these regions were 
lower for IL-4 (E&F) and IL-10 (G&H).  Sertraline administration also normalized the aberrant 
protein to levels similar as the control+Veh group.  All data are presented as mean ± SEM.  *p < 
0.05 between the PTSD groups.  #p < 0.05 between the vehicle groups. 
Although animal models have certain well-understood limitations, a major component missing 
from human PTSD research is the ability to ascertain physiological data directly from specific 
brain regions immediately after a stressful event.  The majority of the human physiological data 
gathered in vivo is derived from saliva, blood and urine, which may not accurately reflect 
neurotransmitter modulation in the brain and certainly cannot distinguish between changes in 






Figure 5.6: In the PFC, the level of 5-HT (A) was significantly lower in the PTSD+Veh vs. the 
control+Veh group.  Conversely, the level of NE (B) was significantly higher in the PTSD+Veh 
group.  Sertraline expectedly raised 5-HT levels in the PTSD+Sert and control+Sert groups to 
levels higher than the control+Veh group (A), but it also elevated NE in the PTSD+Sert and 
control+Sert groups to levels higher than the control+Veh group (B).  In the hippocampus, 5-HT 
(C) was significantly lower in the PTSD+Veh vs. the control+Veh group, while NE (D) was 
higher.  Similar to results in the PFC, sertraline normalized 5-HT to pre-stress levels, but it 
doubled NE in the control+Sert group and more than tripled NE in the PTSD+Sert group 
compared to the control+Veh group (D).  All data are presented as mean ± SEM.  *p < 0.05 
between the PTSD groups.  #p < 0.05 between the vehicle groups. 
model, and to our knowledge, we are the first to report the modulation of biogenic amines and 
inflammatory components in response to sertraline administration in the brains of PTSD animals.  
Three novel and important findings emerged from this study.  First, 5-HT suppression in the 
brain regions examined was normalized with sertraline, but NE levels also significantly 




evidenced by decreased PICs and elevated AICs.  Lastly, despite attenuating inflammatory 
markers, sertraline provided no positive benefit in relation to anxiety or behavior.    
The modulation of various neurotransmitters observed with the predator 
exposure/psychosocial stress model is in concert with many of the neurotransmitter changes seen 
in human PTSD patients (Arora et al., 1993; Geracioti et al., 2001; Geracioti et al., 2013; 
Yehuda, Southwick, Giller, Ma, & Mason, 1992).  Previous research has shown that stress blocks 
long-term potentiation (LTP) in the hippocampus as well as impairs hippocampal function 
(Diamond, Campbell, Park, Halonen, & Zoladz, 2007; Kim & Diamond, 2002). The 
hippocampus, the primary region for spatial and long-term memory storage, expresses all of the 
5-HT receptor families and reflects overall serotonergic functions relating to cognition and mood 
in this region (Berumen, Rodriguez, Miledi, & Garcia-Alcocer, 2012).  During stress, 
glucocorticoid production can reduce the excitability of hippocampal neurons, and 5-HT may 
have a protective effect against such damage by activating 5-HT1A receptors (Joca, Ferreira, & 
Guimaraes, 2007).  Persistent activation of the HPA axis and excessive production of 
glucocorticoids, however, may directly reduce hippocampal 5-HT levels and adversely affect 
normal serotonergic transmission, thus contributing to heightened fear, depressed mood, and 
reduced resilience.  The hippocampus also contains multiple NE receptors which, when activated 
during stress, may contribute to the reinforcement of long-term memories (Jurgens et al., 2005).  
In a study by Geracioti et al. involving male combat veterans with PTSD, CSF concentrations of 
NE were significantly higher vs. controls (Geracioti et al., 2001).  This finding could possibly 
explain why memories formed during extremely stressful events persist over time.  Other 




excretion, exaggerated biochemical responses to yohimbe, and clinical efficacy of adrenergic 
blockers (Southwick et al., 1999).   
The PFC is responsible for executive functions such as consequences, drive, and social 
“control.”  It is highly innervated by serotonergic neurons from the raphe nuclei, and it expresses 
an abundance of 5-HT receptors.  The serotonergic neurons and 5-HT receptors, specifically the 
5-HT1A and 5-HT2A receptors, are key modulators of the PFC-amygdala-corticolimbic circuit 
involved in threat and emotional responses (Fisher et al., 2011).  PTSD-related aberrancies in 
this serotonergic system may cause inappropriate or incomplete extinction of conditioned fear.  
The PFC also contains NE receptors and receives input from NE neurons from the LC, which are 
activated during the stress response (Finlay, Zigmond, & Abercrombie, 1995).  Pathogical or 
stress-related elevations of NE in the PFC, however, may inhibit working memory and 
performance (Zhang, Cordeiro Matos, Jego, Adamantidis, & Seguela, 2013).  Current 
neuroimaging research indicates that the PFC is hyporesponsive during symptomatic PTSD 
states and that this responsiveness is inversely proportional to symptom severity (Shin, Rauch, & 
Pitman, 2006).  Whether marked elevations in NE directly or indirectly diminish PFC 
responsiveness and subsequent performance on cognitive emotional tasks remains unclear.     
The role of inflammation in pathological conditions such as cardiovascular disease, 
diabetes mellitus, metabolic syndrome, and neurological disease is well established (Agarwal et 
al., 2011; Alexopoulos et al., 2012; Elks & Francis, 2010; Pall & Satterlee, 2001).  We recently 
demonstrated oxidative stress and inflammation were up-regulated in the brain and systemic 
circulation of rats subjected to the predator exposure model (Wilson et al., 2013).  In chronic 
stress-related conditions such as PTSD, a sustained sympathoexcitatory state can alter the 




evidence that cytokines and inflammation may be directly linked to psychiatric disorders, but 
whether they are causal or nonspecific immunological side-effects remains unresolved 
(Schiepers, Wichers, & Maes, 2005).  Inflammatory cytokine levels have been shown to be 
inversely proportional to 5-HT levels, and it is hypothesized that PICs can diminish tryptophan 
by activating the tryptophan-metabolizing enzyme indoleamine-2,3-dioxygenase (IDO) (Heyes 
et al., 1992).  There is also evidence that PICs counteract the negative feedback of 
glucocorticoids on the HPA axis, altering its function (A. H. Miller, Pariante, & Pearce, 1999).  
In our previous work, we found that valproic acid (VA) attenuated inflammation, but it differed 
from sertraline in that it did not result in noradrenergic hyperresponsiveness and actually 
modulated NE to levels similar to untreated controls.  In addition, VA lowered anxiety and 
resulted in vast improvements on the EPM (Wilson, McLaughlin, Ebenezer, Nair, & Francis, 
2014).  The fact that both of these compounds decreased inflammatory components but did not 
equally improve EPM performance indicates inflammation and oxidative stress may be 
contributors, but not the sole causal factors in terms of PTSD pathophysiology. 
We have demonstrated that sertraline increases 5-HT and NE, and that it attenuates 
inflammation in the hippocampus, PFC, and CSF.  Based on these mechanisms, its 
administration should result in decreased anxiety and improved resilience.  In our experiments, 
however, we observed no improvement on the EPM that indicated reduced anxiety in the rats.  
The EPM is widely used as a measure to test fear or anxiety and has been extensively validated 
for use in rats (Korte & De Boer, 2003; Pellow, Chopin, File, & Briley, 1985).  Anxiogenic 
compounds or procedures can increase avoidance of the fear-provoking open arms, whereas 
anxiolytic compounds or procedures can increase open arm exploration (Pellow et al., 1985).  It 




et al. demonstrated the ineffectiveness of clonidine and amitriptyline, but showed a marked 
improvement in behavior with tianeptine (Zoladz, Fleshner, & Diamond, 2013).  The anxiolytic 
effects of increased 5-HT and attenuated inflammation should have resulted in increased open 
arm exploration compared to the PTSD+Veh group.  The fact that no significant changes were 
noted between the treated and untreated PTSD groups suggests other mechanisms might be 
acting as endogenous anxiogenic agents.  One such mechanism might be elevated CNS NE and 
increased sympathetic tone.  Noradrenergic hyperresponsiveness has previously been shown to 
contribute to PTSD pathophysiology (Southwick et al., 1993).  It has also been suggested that the 
LC neurons, responsible for CNS NE production, constitute the first or second step of the PTSD 
circuit (Bracha, 2005).  Our findings of elevated NE in the hippocampus, PFC, and CSF despite 
sertraline administration provide sound evidence that exaggerated sympathoexcitation may be a 
primary reason underlying the modest efficacy of SSRIs in PTSD.            
5.5 CONCLUSIONS 
We utilized a predator exposure/psychosocial stress animal model of PTSD to analyze the 
effects of sertraline on neurotransmitter modulation and inflammation in the rat hippocampus, 
PFC, CSF, and plasma.  We found that sertraline increased 5-HT and NE levels in the 
hippocampus, PFC, and CSF.  We also discovered that sertraline attenuated inflammation by 
lowering PICs and elevating AICs.  Despite these seemingly beneficial changes, however, 
anxiety did not diminish in the PTSD+Sert vs. the PTSD+Veh groups.  We propose that 
noradrenergic hyperresponsiveness, evident by exaggerated levels of NE present in the 
hippocampus, PFC, and CSF, might be a primary factor in persistent anxiety and a major reason 
that SSRIs have demonstrated poor efficacy in PTSD.  To our knowledge, this is the first study 




might allow for more targeted pharmacologic therapies with an emphasis on inflammatory 
suppression and control of sympathetic drive.  It would be an oversimplification, nonetheless, to 
presume that a persistent noradrenergic tone is the sole causal factor in PTSD development.  The 
autonomic nervous system (ANS), endocrine system, and immune system are indelibly linked 
with CNS disorders and identifying one system as the cause of PTSD might be impossible.  
Overall, our results demonstrate that there are CNS-specific modifications in neurotransmitters, 
immunomodulators, and ANS activity in response to sertraline in the predator 
exposure/psychosocial stress model.  Further research is critical to delineate, if possible, which 
of these systems actually contributes to PTSD pathophysiology and which are producing 
nonspecific responses common to multiple psychiatric etiologies.  In addition, direct 
comparisons with SSRIs and other compounds demonstrating effectiveness in PTSD such as VA 
and tianeptine are warranted.   
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SUMMARY AND CONCLUSIONS 
 
6.1 OVERALL FINDINGS  
Post-Traumatic Stress Disorder (PTSD) is a disorder that does not discriminate based on 
age, race, sex, occupation, or nationality.  According to the National Center for PTSD, it is 
estimated that approximately 60% of men and 50% of women in the U.S. will face some type of 
serious traumatic event in their lives.  As a result, approximately 5.2 million people  (2%) in the 
U.S. have PTSD in a given year, and 20-25 million (7-8%) will experience PTSD during their 
lifetime.  For combat veterans, estimates range from 11-20% (Veterans Affairs, 2014).  PTSD, 
an anxiety disorder recently reclassified as a trauma- and stressor-related disorder, can develop in 
response to real or perceived life-threatening situations.  According to the Diagnostic and 
Statistical Manual of Mental Disorders 5 (DSM-5), a diagnosis of PTSD necessitates exposure to 
a life-threatening event, intrusive recollections of the event, avoidance of associated stimuli and 
numbing of general responsiveness, negative cognitions/mood, hyperarousal not present before 
the trauma, and a significant social impairment.  All of these symptoms must persist for at least 
30 days and not be due to illness, medication, or substance abuse (American Psychiatric 
Association, 2013).  To date, no definitive diagnostic biomarkers have been identified for PTSD.  
Recent research, however, points toward physiological abnormalities in the hypothalamic-
pituitary-adrenal (HPA) axis, sympathoadrenal medullary system, immune system, and brain 
neurotransmitters that may be implicated in the disorder (Liberzon, Abelson, Flagel, Raz, & 
Young, 1999; Oosthuizen, Wegener, & Harvey, 2005; Sondergaard, Hansson, & Theorell, 2004; 
Wilson et al., 2013, 2014).  Current therapies include drugs (SSRIs) and cognitive behavioral 
approaches, but due to varied backgrounds, experiences, epigenetic differences, and high 




As such, a greater understanding of the molecular, behavioral, and environmental relationship 
inherent in the disorder is paramount for future prevention and treatment strategies.  
 Exposure to psychologically traumatic events, such as those experienced during combat 
or other situations posing a legitimate threat to safety and survival, place individuals at 
significant risk for developing PTSD.  A growing body of evidence suggests that exposure to 
traumatic stressors and subsequent psychological trauma may result in increased morbidity and 
mortality.  Much of the data available suggest traumatic exposure and subsequent PTSD may 
lead to increased incidence of cardiovascular disease, diabetes, chronic fatigue syndrome, and 
other conditions (Dansie et al., 2012; Edmondson & Cohen, 2013; Gupta, 2013; Lukaschek et al., 
2013).  Most of these diseases have detrimental inflammatory components that may exacerbate 
their progression.  Inflammation is a critical component of the immune response, but acute and 
chronic inflammation can damage cellular mechanisms.  Stressful events affect the immune 
system by reducing the cellular response to mitogen stimulation, decreasing production of 
natural killer cell activity and altering levels of cytokines.  Cytotoxic T lymphocytes, which 
regulate the balance between Th1 and Th2 cells, are altered by stress leading to a Th2 dominant 
response, resulting in an unrestrained production of pro-inflammatory cytokines (PICs).  These 
PICs, especially the interleukins, have been shown to play an important role in modulating 
disease processes.  An important and detrimental consequence of increased cytokine production 
is the induction of nitric oxide (NO) and reactive oxygen species (ROS) (Hu, Peterson, & Chao, 
1998; Mokuno et al., 1994).  
 Chapter two was our initial experiment with the predator exposure/psychosocial stress 
animal model, and the primary focus was to analyze inflammatory components and reactive 




stress and inflammation in other pathological conditions such as cardiovascular disease, diabetes 
mellitus, metabolic syndrome, and neurological diseases are well established (Agarwal, Welsch, 
Keller, & Francis, 2011; Alexopoulos et al., 2012; Elks & Francis, 2010; Pall & Satterlee, 2001).  
We hypothesized similar inflammatory mechanisms may also be implicated in PTSD.  First, we 
validated stress induction via an EPM and determined plasma corticosterone levels were elevated 
in the PTSD group.  In addition, growth rate and thymus weights were lower in the PTSD group, 
while adrenal gland weight was higher vs. controls.  The abnormal growth rates confirmed HPA 
axis hyperactivity.  Higher levels of CRH can inhibit feeding behavior, even in food-deprived 
animals (Krahn, Gosnell, & Majchrzak, 1990; Mazjoub, 2006).  Increased adrenal gland weight 
may be due to excessive glucocorticoid production without proper negative feedback from the 
hypothalamus and pituitary, resulting in adrenal hypertrophy and hyperplasia (Ulrich-Lai et al., 
2006).  The substantive decrease seen in thymus weight may be a result of increased oxidative 
stress or cortisol toxicity causing thymocyte apoptosis (Salgo & Pryor, 1996).  We discovered 
that damaging ROS in the hippocampus, PFC, and adrenal glands were upregulated in response 
to the predator exposure/psychosocial stress regimen.  We also found that oxidative stress in the 
blood increased in a time-dependent manner in the PTSD animals.  In the brain, mRNA and 
protein for cytokines and cytokine-producing mechanisms were significantly elevated, 
demonstrating a neuroinflammatory component in PTSD.  Taken together, these data 
demonstrated aberrancies in both the HPA axis and immune system during PTSD progression 
and confirmed the fact that inflammation and oxidative stress, whether causal or resultant, may 
play a key role in the development and exacerbation of the disorder. 
 Chapter three discusses the interaction between various neurotransmitters in the primary 




model.  In the brain, neurotransmitter modulation may play a critical role in PTSD development, 
and they are currently the primary target for pharmacologic interventions.  It remains unclear, 
however, exactly which neurotransmitters are up- or down-regulated during PTSD progression. 
5-HT is the principle regulator of mood.  A study by Peirson et al. (Peirson & Heuchert, 2000) 
found lower platelet 5-HT2 receptor function was associated with depressed mood, while 
Williams et al. (Williams et al., 2006) demonstrated higher blood 5-HT levels were correlated 
with better mood.  In addition, elevated levels of NE and DA have been associated with 
hyperarousal, intrusive recollections, and psychosis (Paterlini et al., 2005; Southwick et al., 
1999).  We found that 5-HT decreased and NE increased in both the hippocampus and PFC, 
providing evidence that the neurotransmitters previously implicated in PTSD pathophysiology 
were in fact modulated in response to persistent stressors.  In addition, we determined that 
neurotransmitters were differentially expressed in the hippocampus and PFC.  In the 
hippocampus, 5-HT and the DA metabolite HVA were lower in the PTSD group vs. controls.  
Conversely, the levels of NE and the DA metabolite DOPAC were significantly higher in the 
PTSD group.  In the PFC, 5-HT was significantly lower, while NE was higher in the PTSD 
group vs. controls.  The levels of DA and the DA metabolite DOPAC were significantly higher 
in the PTSD group.  The neurotransmitter data were supported by the down-regulation of 
tryptophan hydroxylase, the rate-limiting enzyme for 5-HT, and the up-regulation of tyrosine 
hydroxylase, the rate-limiting enzyme for NE and DA.  It would be an oversimplification, 
nonetheless, to presume that neurotransmitter modulation is the sole causal or resultant factor in 
PTSD development, as HPA axis, sympathoadrenal medullary pathway, and immune system 




 In chapter four we demonstrated that HDAC inhibition could decrease inflammation and 
oxidative stress and modulate neurotransmitters, resulting in decreased anxiety and improved 
performance in the EPM.  Gene expression is regulated via highly controlled 
acetylation/deacetylation of histone N-terminal tails, which either increases or decreases gene 
availability (de Ruijter, van Gennip, Caron, Kemp, & van Kuilenburg, 2003).  
Acetylation/deacetylation is accomplished by histone acetyltransferases (HAT) and histone 
deacetylases (HDAC), which enable and restrict genome access, respectively.  When oxidative 
stress and inflammation are increased, upregulated PICs can correspond with heightened HDAC 
activity and NF-κB transcription, resulting in perpetual PIC production (Keslacy, Tliba, 
Baidouri, & Amrani, 2007).  This study was conducted to test alternative pharmacologic 
therapies for PTSD, as the currently approved selective-serotonin reuptake inhibitors (SSRI) 
have proven nominally effective (Tawa & Murphy, 2013).  Previous data from our lab 
demonstrated that HDACi were effective at reducing inflammation and oxidative stress 
(Cardinale et al., 2010), and we hypothesized it may have a similar effect in PTSD.  We found 
that increased oxidative stress and inflammation in the brain and blood in response to 
psychological stress are attenuated with VA, possibly due to attenuated NF-κB transcription.  In 
addition, the aberrant neurotransmitter profile of increased catecholamines and decreased 5-HT 
was normalized with VA.  The mechanism responsible for the neurotransmitter modulation may 
be HDACi interaction with the rate-limiting enzymes (Akiba et al., 2010; Covington et al., 
2009).  VA also seems to enhance resiliency behavior as indicated by reduced anxiety levels in 
the PTSD+VA group.  These findings indicate VA may be a promising therapy with broad-




  In chapter five, we determined that a possible mechanism responsible for the negligible 
effects of SSRIs in some PTSD patients might be an overactive sympathetic drive.  We utilized 
the predator exposure/psychosocial stress model of PTSD to analyze the effects of sertraline on 
neurotransmitter modulation and inflammation in the rat hippocampus, PFC, CSF, and plasma.  
We found that sertraline increased 5-HT and NE levels in the hippocampus, PFC, and CSF.  We 
also discovered that sertraline attenuated inflammation by lowering PICs and elevating anti-
inflammatory cytokines (AIC).  Despite these seemingly beneficial changes, however, anxiety 
did not diminish in the PTSD+Sert vs. the PTSD+Veh groups.  We propose that noradrenergic 
hyperresponsiveness, evident by exaggerated levels of NE present in the hippocampus, PFC, and 
CSF, might be a primary factor in persistent anxiety and a major reason that SSRIs have 
demonstrated poor efficacy in PTSD.  This insight might allow for more targeted pharmacologic 
therapies with an emphasis on inflammatory suppression and control of sympathetic drive.  It 
would be an oversimplification, nonetheless, to presume that a persistent noradrenergic tone is 
the sole causal factor in PTSD development.  The autonomic nervous system (ANS), endocrine 
system, and immune system are indelibly linked with CNS disorders and identifying one system 
as the cause of PTSD might be impossible.  Overall, our results demonstrate that there are CNS-
specific modifications in neurotransmitters, immunomodulators, and ANS activity in response to 
sertraline in the predator exposure/psychosocial stress model.  Further research is critical to 
delineate, if possible, which of these systems actually contributes to PTSD pathophysiology and 







6.2 SIGNIFICANCE OF RESEARCH AND FUTURE DIRECTIONS 
 Current treatment regimens for PTSD are focused primarily on counseling-based 
therapies that help break the association between the traumatic event and the lingering anxiety, 
hyperarousal, intrusive thoughts, and other symptoms.  These approches have proven effective to 
a degree, but they do not take into account the aberrant pathophysiological profile of PTSD.  The 
drugs that are currently available can suppress some of the comorbid symptoms such as 
depression, but they fail to correct the underlying molecular mechanisms in PTSD.  This work 
was significant because we used an animal model to elucidate some of the pathophysiological 
mechanisms involved in PTSD progression, discovered a rationale as to why SSRIs might be 
ineffective in treating PTSD, and demonstrated the efficacy of an alternative drug in attenuating 
inflammatory cytokines, reactive oxygen, and neurotransmitter fluctuations.  Our findings, 
however, merely scratch the surface of this complex disorder and continued research is 
paramount. 
 One of our original goals was to locate a specific biomarker that could be diagnostic for 
PTSD.  One project that we have on the immediate horizon is the total RNA sequencing and 
gene comparison between PTSD animals and controls.  Based on the pathophysiological 
components we have previously described, we hypothesize that there might be gene expression 
changes occuring as the disorder progresses.  We aim to analyze the potential changes, isolate 
certain genes, and attempt to identify a small number of genes that are characteristic of PTSD.  
We will also evaluate whether differentially expressed genes might be correlated with behavior.  
Our long-term goal concerning gene expression analysis is to block or overexpress certain genes 




The potential to diagnose PTSD both psychologically and physiologically could 
drastically broaden treatment options and hopefully improve recovery.  PTSD, however, is a very 
complex disorder with multiple system aberrancies occuring simutaneously.  The truth is there 
might not be a single physiologic biomarker that is indicative of and exclusively diagnostic for 
PTSD.  Taken together, the data presented herein will help add to the collective knowledge base 
concerning PTSD and assist in the constant pursuit of understanding and treating this 
confounding disorder.  
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